Atherosclerosis home=>news=>atherosclerosis=>pathophysiology
(affects
Type 1 AND Type 2 Diabetics)
General Treatment Pathophysiology
Pathophysiology
Interleukin-1Receptor
Antagonist in Type 2 Diabetes Mellitus (NEJM 356:1517-1526,
2007)Background The expression of
interleukin-1receptor antagonist is
reduced in pancreatic islets of patients with type 2
diabetes mellitus, and high glucose
concentrations induce the production of
interleukin-1 in human pancreatic beta cells, leading to
impaired insulin secretion, decreased cell
proliferation, and apoptosis. Methods
In this double-blind, parallel-group trial involving
70 patients with type 2 diabetes, we randomly
assigned 34 patients to receive 100 mg of
anakinra (a recombinant human interleukin-1receptor
antagonist) subcutaneously once daily for 13 weeks
and 36 patients to receive placebo. At
baseline and at 13 weeks, all patients underwent
an oral glucose-tolerance test, followed by an
intravenous bolus of 0.3 g of glucose per
kilogram of body weight, 0.5 mg of glucagon,
and 5 g of arginine. In addition, 35 patients underwent
a hyperinsulinemiceuglycemic clamp study. The
primary end point was a change in the level of
glycated hemoglobin, and secondary end points
were changes in beta-cell function, insulin
sensitivity, and inflammatory markers. Results
At 13 weeks, in the anakinra group, the glycated
hemoglobin level was 0.46 percentage point
lower than in the placebo group (P=0.03);
C-peptide secretion was enhanced (P=0.05), and there
were reductions in the ratio of proinsulin to
insulin (P=0.005) and in levels of
interleukin-6 (P<0.001) and C-reactive protein (P=0.002).
Insulin resistance, insulin-regulated gene expression
in skeletal muscle, serum adipokine levels, and the
body-mass index were similar in the two study
groups. Symptomatic hypoglycemia was not
observed, and there were no apparent drug-related serious
adverse events. Conclusions The
blockade of interleukin-1 with anakinra improved glycemia
and beta-cell secretory function and reduced markers
of systemic inflammation. (ClinicalTrials.gov
number, NCT00303394 [ClinicalTrials.gov] )
- The
Inflammation Link: Association between psoriasis,
diabetes mellitus, and atherosclerosis - A
case-control study(JAAD 56:
629-634 ,April 2007) Background Previous
reports demonstrated an association between
psoriasis and other diseases including heart
failure and diabetes mellitus.Objectives
Our aim was to describe the association between
psoriasis, diabetes mellitus, and atherosclerosis
in Israel. Methods A
cross-sectional study was performed utilizing the
database of Maccabi Healthcare Services (MHS), a
large health provider organization in Israel.
Case patients were defined as subjects who were
diagnosed with psoriasis. Patients with diabetes
and atherosclerosis were identified by using the
MHS diabetes and cardiovascular registries,
respectively. The control group included MHS
enrollees without psoriasis. The proportion of
diabetes and atherosclerosis among case and
control groups was compared. Chi-square tests
were used to compare categorical parameters.
Logistic regression models were used for
multivariate analyses. Results
The study included 46,095 patients with psoriasis
(case patients) and 1,579,037 subjects without
psoriasis (control patients). The age-adjusted
proportion of diabetes was significantly higher
in psoriasis patients as compared with the
control group (odds ratio [OR] 1.27, 95%
confidence interval [CI] 1.1-1.48). The
age-adjusted proportion of atherosclerosis was
significantly higher in psoriasis patients as
compared with the control group (OR 1.28, 95% CI
1.04-1.59). In patients with psoriasis, a
multivariate logistic regression model
demonstrated an association between diabetes and
the multiple use of very potent topical steroids
(P < .05) or use of systemic medication
for psoriasis (methotrexate, cyclosporine or
acitretin) (P < .001). A similar model
demonstrated an association between
atherosclerosis and the use of phototherapy (P
< .001). Limitations Our
study was based on a computerized database. The
diagnosis of psoriasis was based
on digitally transmitted data. Therefore
overestimation (false-positive cases) and
underestimation (false-negative cases) of
psoriasis patients may exist, thereby being a
source for information bias. A second limitation
is selection bias that may occur due to the
possibility that reporting of both psoriasis and
associated illnesses is higher in individuals who
are seeking medical care. A third limitation
concerns the causal effect between occurrence of
psoriasis and atherosclerosis or diabetes. The
dataset of MHS records diagnoses only from 1997
and does not record the date of disease onset. Conclusions
Our study supports previous reports for an
association between psoriasis and atherosclerosis
and psoriasis and diabetes. Further study is
needed to support this observation.
Insulin
resistance measured by the euglycaemic insulin clamp
predicts subsequent CHD in elderly men. Proinsulin
provides a better prediction of CHD than insulin. (Diabetologia [2005]48:1432-0428
(Online)) Aims/hypothesis The
association between CHD and insulin sensitivity (Si)
measured by the euglycaemic insulin clamp has not been
examined previously. Earlier studies found a relationship
between CHD and elevated plasma insulin, an analysis that
may have been confounded by co-determination of
proinsulin, which has evolved as a stronger predictor of
CHD. The aim was to determine the longitudinal
relationships between Si, intact proinsulin,
3233 split proinsulin, specific insulin and
subsequent CHD. Methods This
was a population-based cohort study of 815 men in
Uppsala, Sweden, aged 70 years at baseline with a
follow-up of up to 10 years. Baseline insulin sensitivity
was determined by euglycaemic insulin clamp. Fasting
proinsulin, 3233 split proinsulin and specific
insulin concentrations were analysed using specific
two-site immunometric assays. CHD was taken as diagnosed,
if stated (in the event of death) on the Cause of Death
Registry, or for subjects hospitalised for the first time
with CHD, if CHD was recorded in the Hospital-Discharge
Registry. The associations were analysed using Cox's
proportional hazards, presented as hazard ratios (HRs)
with their 95% CIs for a one-SD increase in the
predictor. Results In
multivariate analysis, Si (HR:0.80,
CI:0.650.97) adjusted for serum cholesterol,
systolic blood pressure, fasting plasma glucose, BMI and
smoking predicted CHD. Intact proinsulin (HR:1.18,
CI:1.011.38), adjusted as the model above,
predicted CHD, whereas 3233 split proinsulin
(HR:1.13, CI:0.951.35) or specific insulin
(HR:1.07, CI:0.891.30) did not. Conclusions/interpretation Insulin
resistance measured by the euglycaemic insulin clamp
predicts subsequent CHD in elderly men. Proinsulin
provides a better prediction of CHD than insulin.
- Resistin
Is an Inflammatory Marker of Atherosclerosis in
Humans (Circulation
[2005]111:932-939.) Background
Resistin, a plasma protein, induces
insulininsulin-resistant rodents and
resistance in rodents. Recent reports suggest
that circulating levels of resistin
are elevated in obese and humans. Whereas rodent
resistin is made in adipocytes,adipocyte and
macrophage macrophages are a major source of
human resistin. Given the convergence
of function, resistin mayResults
We examined provide unique insight into links
between obesity, inflammation, and
atherosclerosis in humans. Methods
and whether plasma resistin(CAC), a
quantitative index levels were
associated with metabolic and inflammatory
markers, as well as with coronary
artery calcification of atherosclerosis, in 879
asymptomatic subjects in the Study of
Inherited Risk of Coronary Atherosclerosis.
Resistin levels were positively
associated with levels of inflammatoryand
lipoprotein-associated phospholipase
markers, including soluble tumor necrosis
factor-alpha receptor-2 (P<0.001),
interleukin-6 (P=0.04), Aratio and 95%
confidence interval in 2 (P=0.002),
but not measures of insulin resistance in
multivariable analysis. Resistin levels also were
associated (odds ordinal
regression)1.52], P=0.03) and further
control for with increasing CAC after
adjustment for age, sex, and established risk
factors (OR, 1.23 [CI, 1.03 to metabolic syndrome
and plasma C-reactive proteinmetabolic syndrome,
resistin levels (CRP) levels (OR, 1.25 [CI, 1.04
to 1.50], P=0.01). In subjects with
further predicted CAC,inflammation and are
predictive of whereas CRP levels did not. Conclusions
Plasma resistin levels are correlated with markers
of coronary atherosclerosisinflammation, and
atherosclerosis. in humans,
independent of CRP. Resistin may represent a
novel link between metabolic signals,
Further studies are needed to define the
relationship of resistin to clinical
cardiovascular disease.
Tumor Necrosis
Factor-alpha Receptor 1 Is a Major Predictor of Mortality
and New-Onset Heart Failure in Patients With Acute
Myocardial Infarction(Circulation
[2005]111:863-870)Background
Tumor necrosis factor alpha (TNF-alpha) activation is
an independent prognostic indicator of mortality in
patients with heart failure (HF). Despite the
recognition that several TNF family cytokines
are elevated during myocardial infarction, their
role in predicting subsequent prognosis in these setting
remains poorly understood. Methods
and Results We performed a systematic
evaluation of TNF-alpha and its type 1 and 2
soluble receptors, together with interleukin
(IL)-6, IL-1 receptor antagonist, and IL-10, in 184
patients (132 men; mean age, 64±12) consecutively admitted
for myocardial infarction. We correlated their values
to short- and long-term incidence of death and HF
(primary outcome). In 10 patients, we also
studied the presence of transcardiac gradients
for TNF-alpha and its soluble receptors. The control
group comprised 45 healthy subjects who were
sex and age matched (33 men; mean age, 65±6
years) to the patients. All tested cytokines
were increased in patients, and no transcardiac or systemic
AV difference was found. After a median follow-up of
406 days (range, 346 to 696 days), 24 patients died
and 32 developed HF. Univariate analysis
showed that all cytokines were related to
outcome, whereas after adjustment for baseline and
clinical characteristics, sTNFR-1 remained the
only independent predictor of death and HF
(hazard ratio, 2.9; 95% CI, 1.9 to 3.8, tertile 1
versus 3), together with left ventricular ejection
fraction, Killip class, and creatine kinase-MB
at peak. Conclusions
sTNFR-1 is a major short- and long-term predictor of
mortality and HF in patients with acute myocardial
infarction.
- Impaired
insulin-induced vasodilation in small coronary
arteries of Zucker obese rats is mediated by
reactive oxygen species (Am J Physiol Heart Circ Physiol
[2005]288:H854-H860)Insulin resistance (IR) and
associated hyperinsulinemia are major
risk factors for coronary artery disease.
Mechanisms linking hyperinsulinemia to
coronary vascular dysfunction in IR are unclear.
We evaluated insulin-induced vasodilation in
isolated small coronary arteries (SCA;
~225 µm) of Zucker obese (ZO) and
control Zucker lean (ZL) rats. Vascular responses
to insulin (0.1100 ng/ml), ACh
(109105 mol/l),
and sodium nitroprusside (108104
mol/l) were assessed in SCA by measurement
of intraluminal diameter using
videomicroscopy. Insulin-induced dilation was
decreased in ZO compared with ZL rats,
whereas ACh and sodium nitroprusside elicited
similar vasodilations. Pretreatment of arteries
with SOD (200 U/ml), a scavenger of
reactive oxygen species (ROS), restored
the vasorelaxation response to insulin in ZO
arteries, whereas ZL arteries were
unaffected. Pretreatment of SCA with N-nitro-L-arginine methyl ester (100
µmol/l), an inhibitor of endothelial
nitric oxide (NO) synthase (eNOS), elicited a
vasoconstrictor response to insulin that
was greater in ZO than in ZL rats.
This vasoconstrictor response was reversed to
vasodilation in ZO and ZL rats by
cotreatment of the SCA with SOD or apocynin (10
µmol/l), a specific inhibitor of vascular NADPH
oxidase. Lucigenin-enhanced
chemiluminescence showed increased basal ROS
levels as well as insulin (330 ng/ml)-stimulated
production of ROS in ZO arteries that
was sensitive to inhibition by apocynin. Western
blot analysis revealed increased eNOS expression
in ZO rats, whereas Mn SOD and Cu,Zn
SOD expression were similar to ZL
rats. Thus IR in ZO rats leads to decreased
insulin-induced vasodilation, probably
as a result of increased production of ROS
by vascular NADPH oxidase, leading to decreased
NO bioavailability, despite a
compensatory increase in eNOS expression.
Circulating
Mononuclear Cells In The Obese Found To Be In
Proinflammatory State, Contributing To Diabetes And Heart
Disease (Circulation
[2004] 110:1564-1571) Background
In view of the increase in plasma concentrations of
proinflammatory mediators tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6),
and C-reactive protein (CRP) in obesity, we
investigated whether peripheral blood mononuclear cells
(MNC) from obese subjects are in a
proinflammatory state. Methods and
Results MNC were prepared from fasting
blood samples of obese (n=16; body mass index
[BMI]=37.7±5.0 kg/m2) and
normal-weight control (n=16; BMI=23.8±1.9 kg/m2)
subjects. Nuclear factor kB (NF-kB) binding to DNA in nuclear extracts
was elevated (P<0.05) and the inhibitor of NFkB-ß (IkB-ß)
was significantly lower (P<0.001) in the obese
group. Reverse transcriptionpolymerase chain
reaction revealed elevated levels of migration
inhibitor factor (MIF), IL-6, TNF-a, and matrix metalloproteinase-9 (MMP-9)
mRNA expression in the obese subjects (P<0.05).
Plasma concentrations of MIF, IL-6, TNF-a, MMP-9, and CRP were also significantly
higher. Plasma glucose, insulin, and free
fatty acids (FFAs) were measured, and
homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated. Plasma FFA
concentration related significantly to BMI,
IL-6, and TNF-a mRNA expression and plasma CRP levels
but not to HOMA-IR. On the other hand, the
inflammatory mediators were significantly
related to BMI and HOMA-IR. Conclusions
These data show (1) for the first time that MNC
in obesity are in a proinflammatory state with an
increase in intranuclear NF-kB binding, a decrease in IkB-ß, and an increase in the
transcription of proinflammatory genes regulated
by NF-kB; (2) that plasma FFAs are a
modulator of inflammation; and (3) that
insulin resistance is a function of inflammatory mediators.
- Urinary
20-Hydroxyeicosatetraenoic Acid Is Associated
With Endothelial Dysfunction in Humans (Circulation
[2004]110:438-443) Background
20-Hydroxyeicosatetraenoic acid (20-HETE) is
a cytochrome P450 (-hydroxylase) metabolite
of arachidonic acid with
vasoconstrictor activity that may be involved in
the pathogenesis of hypertension. In
humans, there are few data relating
20-HETE to vascular pathophysiology. This study
aimed to determine whether urinary
20-HETE excretion is related to blood
pressure or vascular endothelial function in
humans. Methods and
Results Sixty-six subjects (37
males, 29 females), including 29 with
untreated hypertension, had urinary 20-HETE
excretion measured by gas chromatography/mass
spectrometry. There was no significant
difference for 20-HETE excretion between hypertensive
and normotensive subjects. 20-HETE excretion was
positively related to body mass index and
sodium excretion. There was a
significant inverse association between urinary
20-HETE and endothelium-dependent
vasodilation measured by flow-mediated dilation
of the brachial artery (P=0.006). There
was no association with vasodilator
responses to nitroglycerin. In multiple
regression analysis, 20-HETE remained
an independent predictor of endothelium-dependent
vasodilation after adjustment for age, body
mass index, and blood pressure. When
gender was included in the model, the
relationship between 20-HETE and
flow-mediated dilation was attenuated. Separate
analysis by gender revealed that in women,
hypertensive subjects had
significantly higher 20-HETE excretion than
normotensive subjects, but this was
not seen in men. In women, 20-HETE was positively
related to diastolic and systolic blood pressure.
In men, 20-HETE was positively related to
body mass index. Conclusions
This is the first demonstration of an association
between 20-HETE excretion and in vivo
vascular function in humans. Given the
negative modulatory role of nitric oxide on -hydroxylase, the
present results suggest a potentially important
role for 20-HETE in human vascular
physiology.
Fish intake may
influence risk of Atrial Fibrillation (Circulation [2004]110:368-373) Background
Atrial fibrillation (AF) is the most common arrhythmia
in clinical practice and is particularly common in the
elderly. Although effects of fish intake, including
potential antiarrhythmic effects, may
favorably influence risk of AF, relationships
between fish intake and AF incidence have not been
evaluated. Methods and Results
In a prospective, population-based cohort of
4815 adults >=age 65 years, usual dietary intake was
assessed at baseline in 1989 and 1990. Consumption
of tuna and other broiled or baked fish
correlated with plasma phospholipid long-chain
n-3 fatty acids, whereas consumption of fried fish or
fish sandwiches (fish burgers) did not. AF incidence was
prospectively ascertained on the basis of hospital
discharge records and annual
electrocardiograms. During 12 years follow-up,
980 cases of incident AF were diagnosed. In multivariate
analyses, consumption of tuna or other broiled or
baked fish was inversely associated with
incidence of AF, with 28% lower risk with
intake 1 to 4 times per week (HR=0.72, 95% CI=0.58 to
0.91, P=0.005), and 31% lower risk with intake
>=5 times per week (HR=0.69, 95% CI=0.52 to
0.91, P=0.008), compared with <1
time per month (P trend=0.004). Results were not
materially different after adjustment for
preceding myocardial infarction or congestive
heart failure. In similar analyses, fried fish/fish sandwich
consumption was not associated with lower risk of AF.Conclusions
Among elderly adults, consumption of tuna or
other broiled or baked fish, but not fried fish or fish
sandwiches, is associated with lower incidence
of AF. Fish intake may influence risk of this
common cardiac arrhythmia.
- Data
suggest that AKT may be involved in the
endothelial dysfunction of hypertension (Circulation [2004]109:2587-2593) Background In
hypertension, reduced nitric oxide production
and blunted endothelial vasorelaxation are
observed. It was recently reported
that AKT phosphorylates and activates endothelial
nitric oxide synthase and that impaired
kinase activity may be involved in
endothelial dysfunction. Methods
and Results To identify the
physiological role of the kinase in
normotensive Wistar-Kyoto rats (WKY) and
spontaneously hypertensive rats (SHR),
we used adenoviral vectors to transfer the
human AKT1 gene selectively to the common carotid
endothelium. In vitro, endothelial
vasorelaxations to acetylcholine, isoproterenol,
and insulin were blunted in control
carotids from SHR compared with WKY
rats, and human AKT1 overexpression corrected
these responses. Similarly, blood flow
assessed in vivo by Doppler ultrasound
was reduced in SHR compared with WKY carotids and
normalized after AKT1 gene transfer. In
primary cultured endothelial cells, we
evaluated AKT phosphorylation, activity, and
compartmentalization and observed a
mislocalization of the kinase in SHR. Conclusions
We conclude that AKT participates in the settings
of endothelial dysfunction in SHR rats by
impaired membrane localization. Our
data suggest that AKT is involved in
endothelium dysfunction in hypertension.
Oxidative stress induces insulin
resistance by activating the nuclear factor-kB pathway
and disrupting normal subcellular distribution of
phosphatidylinositol 3-kinase (Diabetologia [2004] 47: 794
- 805)
Aims/hypothesis Oxidative stress is
associated with diabetes, hypertension and
atherosclerosis. Insulin resistance is implicated in the
development of these disorders. We tested the hypothesis
that oxidative stress induces insulin resistance in rats,
and endeavoured to identify mechanisms linking the two. Methods Buthionine
sulfoximine (BSO), an inhibitor of glutathione synthase,
was administered to Sprague-Dawley rats and 3T3-L1
adipocytes. Glucose metabolism and insulin signalling
both in vivo and in 3T3-L1 adipocytes were examined. In
3T3-L1 adipocytes, the effects of overexpression of a
dominant negative mutant of inhibitory kB
(IkB), one role of which is to block
oxidative-stress-induced nuclear factor (NF)-kB
activation, were investigated. Results In
rats given BSO for 2 weeks, the plasma lipid
hydroperoxide level doubled, indicating increased
oxidative stress. A hyperinsulinaemic-euglycaemic clamp
study and a glucose transport assay using isolated muscle
and adipocytes revealed insulin resistance in BSO-treated
rats. BSO treatment also impaired insulin-induced glucose
uptake and GLUT4 translocation in 3T3-L1 adipocytes. In
BSO-treated rat muscle, adipose tissue and 3T3-L1
adipocytes, insulin-induced IRS-1 phosphorylation in the
low-density microsome (LDM) fraction was specifically
decreased, while that in whole cell lysates was not
altered, and subsequent translocation of
phosphatidylinositol (PI) 3-kinase from the cytosol and
the LDM fraction was disrupted. BSO-induced impairments
of insulin action and insulin signalling were reversed by
overexpressing the dominant negative mutant of IkB,
thereby suppressing NF-kB activation. Conclusions/interpretation Oxidative
stress induces insulin resistance by impairing IRS-1
phosphorylation and PI 3-kinase activation in the LDM
fraction, and NF-kB activation is likely to be
involved in this process.
- Endothelial
dysfunction predicts type 2 diabetes in women
independent of other known risk factors,
including obesity and subclinical inflammation.(JAMA [2004] 291:1978-1986) Context
Endothelial dysfunction occurs in diagnosed type
2 diabetes mellitus but may also precede
development of diabetes. Objective
To determine whether elevated plasma levels of
biomarkers reflecting endothelial dysfunction
(E-selectin; intercellular adhesion
molecule 1 [ICAM-1]; and vascular cell adhesion
molecule 1 [VCAM-1]) predict development of type
2 diabetes in initially nondiabetic
women. Design and Setting
Prospective, nested case-control study within
the Nurses' Health Study, an ongoing US study
initiated in 1976. Participants
Of 121 700 women initially enrolled, 32 826
provided blood samples in 1989-1990; of those
free of diabetes, cardiovascular
disease, or cancer at baseline, 737
developed incident diabetes by 2000. Controls (n
= 785) were selected according to
matched age, fasting status, and race.
Main Outcome Measure Risk of
confirmed clinically diagnosed type 2
diabetes by baseline levels of E-selectin,
ICAM-1, and VCAM-1. Results
Baseline median levels of the biomarkers were
significantly higher among cases than among
controls (E-selectin, 61.2 vs 45.4
ng/mL; ICAM-1, 264.9 vs 247.0 ng/mL; VCAM-1,
545.4 vs 526.0 ng/mL [all P
values <=0.004]). Elevated E-selectin and
ICAM-1 levels predicted incident diabetes
in logistic regression models
conditioned on matching criteria and adjusted for
body mass index (BMI), family history
of diabetes, smoking, diet score,
alcohol intake, activity index, and
postmenopausal hormone use. The
adjusted relative risks for incident diabetes in
the top quintile vs the bottom
quintiles were 5.43 for E-selectin (95%
confidence interval [CI], 3.47-8.50), 3.56 for
ICAM-1 (95% CI, 2.28-5.58), and 1.12
for VCAM-1 (95% CI, 0.76-1.66). Adjustment for
waist circumference instead of BMI or further
adjustment for baseline levels of
C-reactive protein, fasting insulin, and
hemoglobin A1c or exclusion of cases
diagnosed during the first 4 years of
follow-up did not alter these associations. Conclusion
Endothelial dysfunction predicts type 2 diabetes
in women independent of other known risk
factors, including obesity and
subclinical inflammation.
Interleukin-6
is a positive regulator of tumor necrosis factor -induced
adipose-related protein in 3T3-L1 adipocytes (FEBS Letters [2004] 560:153-157) Tumor
necrosis factor (TNF)alpha induced adipose-related
protein (TIARP) is a novel TNF-alpha-stimulated protein
in adipocytes. Besides TNFalpha, interleukin (IL)-6 has
recently been shown to be another adipocytokine
implicated in insulin resistance. Therefore, the impact
of IL-6 on TIARP gene expression in 3T3-L1 adipocytes was
determined by quantitative real-time reverse
transcription-polymerase chain reaction. Interestingly,
TIARP mRNA expression was stimulated up to 3.8-fold by
IL-6 in a dose-dependent fashion with significant
stimulation detectable at effector concentrations as low
as 3 ng/ml and maximal effects seen at 100 ng/ml IL-6.
Induction of TIARP mRNA by IL-6 was time-dependent with
significant upregulation occurring as early as 2 h after
effector addition and maximal effects observed at 4 h. In
parallel, TIARP protein synthesis was upregulated with
maximal effects seen after 8 h of IL-6 treatment.
Furthermore, the Janus kinase 2 inhibitor AG490 decreased
TIARP mRNA expression. The increase of TIARP mRNA could
be reversed by withdrawal of IL-6 for 24 h. Furthermore,
TIARP mRNA induction by IL-6 was also seen in brown
adipocytes but not in muscle and liver cells. Taken
together, these results show that TIARP is acutely
regulated in adipose tissue not only by TNFalphabut also
by IL-6 which has been shown to be another important
cytokine implicated in the pathogenesis of insulin
resistance.
- Plasminogen
activator inhibitor correlates with coronary wall
thickening in patients with angiographically
normal coronary arteries (Thrombosis Research [2003]
112: 123-129) Introduction: Angiographically
normal coronary arteries have concealed intimal
thickening that importantly contribute to
coronary arterial disease activity. Increased
plasma levels of plasminogen activator inhibitor
(PAI) are associated with myocardial infarction
and atherosclerosis. However, it remains unclear
whether the PAI contributes to vascular wall
thickening detected by intravascular ultrasound
(IVUS) in normal coronary angiogram. The aim of
this study was to evaluate if the PAI activity
contributes to the extent of atherosclerotic
changes in angiographically normal coronary
arteries using IVUS technique. Materials and
methods: We studied 33 consecutive patients with
normal coronary angiograms. These patients were
divided into a high level of plasma PAI activity
group (H-PAI; n=12) and a normal range of PAI
activity group (N-PAI; n=21), according to the
plasma PAI activity levels. Results: The average
of "percent intima+media area (%I+M
area)" and "maximal intima+media (I+M)
thickness" were significantly greater in the
H-PAI group as compared with those in the N-PAI
group (p<0.05). Minimal lumen diameter and
lumen area were comparable between these groups.
The plasma PAI activity level was the independent
predictor of increase in maximal I+M thickness,
in multiple regression analysis with the
traditional risk factors as covariates.
Conclusions: Thickened intima+media of
angiographically normal coronary arteries were
associated with high plasma level of PAI
activity, independently of other traditional risk
factors. PAI may contribute to the pathogenesis
of coronary intimal thickening that might
increase coronary arterial tone. Author
Keywords: Plasminogen activator
inhibitor; Coronary wall thickening;
Intravascular ultrasound; Normal coronary
angiogram; Quantitative coronary angiography;
Nitric oxides
Beta-blockers
enhance natriuretic peptides' effects during exercise (J
Am Coll Cardiol [2004] 43:353-359) In patients with coronary artery
disease, natriuretic peptide levels in plasma are
increased during exercise, French physicians now show
that treatment with beta-blockers enhances the
natriuretic peptide release, thus decreasing cardiac
load.Cardiac disease is associated with increased resting
levels of atrial and brain natriuretic peptide. Under
stress, cardiomyocytes release both atrial and brain
natriuretic peptide, which exert vasodilator and diuretic
effects, which many be expected to reduce cardiac load.
However, this process in patients with coronary artery
disease has been poorly characterized.Therefore, Dr.
Pierre-Yves Marie and colleagues at UPRES EA in Nancy,
measured natriuretic peptide levels at rest and peak
exercise in 104 patients with chronic coronary artery
disease. They describe their findings in the Journal of
the American College of Cardiology for February 4th.The
best independent predictors of natriuretic peptide
concentrations at rest were aging and the extent of
scarred left ventricular area. "No previous study
has given evidence of the dramatic influence of the
extent of scarred myocardium, as determined by myocardial
SPECT," the authors write.Beta blocker treatment did
not affect natriuretic peptide concentrations at rest.
However, during exercise, the average increase in both
atrial and brain natriuretic peptide was more than
doubled in the 55 patients treated with beta-blockers,
even though their heart rate did not increase as
much."This enhanced secretion of potent vasodilating
and natriuretic agents might constitute an additional and
original mechanism of these drugs for further protecting
diseased hearts against stress," Dr. Marie's group
concludes.
- MCC134
- which inhibits preconditioning - opens cardiac
surface k(ATP) channels but blocks mito k(ATP)
channels reaffirming the dependency of
cardioprotection upon mito rather than surface
k(ATP) channels (Circulation [2003]107(8):1183-8)BACKGROUND: MCC-134
(1-[4-(H-imidazol-1-yl)benzoyl]
-N-methylcyclobutane-carbothioamide), a newly
developed analog of aprikalim, opens surface
smooth muscle-type ATP-sensitive potassium
(K(ATP)) channels but inhibits pancreatic K(ATP)
channels. However, the effects of MCC-134 on
cardiac surface K(ATP) channels and mitochondrial
K(ATP) (mitoK(ATP)) channels are unknown. A mixed
agonist/blocker with differential effects on the
two channel types would help to clarify the role
of K(ATP) channels in cardioprotection. METHODS
AND RESULTS: To index mitoK(ATP) channels, we
measured mitochondrial flavoprotein fluorescence
in rabbit ventricular myocytes. MCC-134 alone had
little effect on basal flavoprotein fluorescence.
However, MCC-134 inhibited diazoxide-induced
flavoprotein oxidation in a dose-dependent manner
(EC(50)=27 micro mol/L). When ATP was included in
the pipette solution, MCC-134 slowly activated
surface K(ATP) currents with some delay (>10
minutes). These results indicate that MCC-134 is
a mitoK(ATP) channel inhibitor and a surface
K(ATP) channel opener in native cardiac cells. In
cell-pelleting ischemia assays, coapplication of
MCC-134 with diazoxide abolished the
cardioprotective effect of diazoxide, whereas
MCC-134 alone did not alter cell death. These
results were reproducible in both rabbit and
mouse myocytes. MCC-134 also attenuated the
effect of ischemic preconditioning against
myocardial infarction in mice, consistent with
the results of cell-pelleting ischemia assays.
CONCLUSIONS: A single drug, MCC-134, opens
surface K(ATP) channels but blocks mitoK(ATP)
channels; the fact that this drug inhibits
preconditioning reaffirms the primacy of
mitoK(ATP) rather than surface K(ATP), channels in the mechanism of cardioprotection.
Stress
upregulates arterial matrix metalloproteinase expression
and activity via endothelin 1-A receptor activation (Am J Physiol Heart Circ
Physiol [2003] 285: H2225 - H2232) Degradation of the extracellular
matrix proteins by matrix metalloproteinases (MMP)
is an important regulatory step in the vascular
remodeling process. Recent studies
demonstrated that ETA receptors regulate cardiac
MMP activity and fibrosis in DOCA-salt hypertension.
However, little is known about endothelin (ET)-1
regulation of vascular MMP activity in
hypertension. Thus early changes in
ET-1-mediated regulation of MMP activity were measured in
borderline hypertensive rats that develop impaired
vasorelaxation and hypertension with chronic
exposure to stress. Experiments were performed
after 10 days of exposure to the behavioral stressor,
air-jet stress, but before the onset of
stress-induced hypertension. Study groups were
1) control (n = 8); 2) air-jet
stress for 10 days (n = 8); 3)
control plus ETA antagonist ABT-627 (n
= 4), and 4) air-jet stress plus ETA
antagonist (n = 4). MMP activity in the
thoracic aorta was assessed by gelatin zymography. MMP
protein and tissue ET-1 levels were evaluated by
immunohistochemistry, and ET receptor density
was determined by immunoblotting. Exposure to
stress caused a twofold increase in plasma ET-1 levels (P
< 0.05), and there was increased ET-1 staining
at the tissue level. Total MMP activity and
expression of MMP-2 and MMP-9 were increased
in the stress group. ETA receptor antagonism
prevented the increase in MMP expression and
activation in the stress group. These results
provide evidence that the MMP system is
activated before the development of hypertension and ET-1
mediates these early events in vascular remodeling.
- Inhibition
of NF-kB activation in macrophages
increases atherosclerosis in LDL
receptordeficient mice (J. Clin. Invest.[2003]112:1176-1185
doi:10.1172/JCI200318580) Atherosclerosis is now generally
accepted as a chronic inflammatory condition.
The transcription factor NF-kB is a key regulator of
inflammation, immune responses, cell survival,
and cell proliferation. To investigate
the role of NF-kB activation in macrophages
during atherogenesis, we used LDL
receptordeficient mice with a
macrophage-restricted deletion of IkB kinase 2 (IKK2), which
is essential for NF-kB activation by
proinflammatory signals. These mice
showed increased atherosclerosis as quantified by
lesion area measurements. In addition, the
lesions were more advanced and showed
more necrosis and increased cell number in
early lesions. Southern blotting revealed that
deletion of IKK2 was approximately 65%
in macrophages, coinciding with a reduction
of 50% in NF-kB activation, as compared
with controls. In both groups, the
expression of differentiation markers, uptake
of bacteria, and endocytosis of modified
LDL was similar. Upon stimulation with
LPS, production of TNF was reduced by
approximately 50% in IKK2-deleted
macrophages. Interestingly, we also found a
major reduction in the anti-inflammatory cytokine
IL-10. Our data show that inhibition
of the NF-kB pathway in macrophages
leads to more severe atherosclerosis in
mice, possibly by affecting the pro-
and anti-inflammatory balance that controls the
development of atherosclerosis.
Tumor Necrosis
Factor-alpha Inhibits Insulins Stimulating Effect
on Glucose Uptake and Endothelium-Dependent Vasodilation
in Humans (Circulation
[2003]108:1815) Background
Inflammatory mechanisms could be involved in
the pathogenesis of both insulin resistance and
atherosclerosis. Therefore, we aimed at
examining whether the proinflammatory cytokine
tumor necrosis factor (TNF)-alpha inhibits
insulin-stimulated glucose uptake and
insulin-stimulated endothelial function in humans.
Methods and Results Healthy,
lean male volunteers were studied. On each
study day, 3 acetylcholine (ACh) or sodium nitroprusside
(SNP) dose-response studies were performed by infusion
into the brachial artery. Before and during the last
2 dose-response studies, insulin and/or TNF-alpha
were coinfused. During infusion of insulin
alone for 20 minutes, forearm glucose uptake
increased by 220±44%. This increase was completely inhibited
during coinfusion of TNF-alpha (started 10 min before
insulin) with a more pronounced inhibition of
glucose extraction than of blood flow.
Furthermore, TNF-alpha inhibited the ACh forearm blood
flow response (P<0.001), and this
inhibition was larger during insulin infusion
(P=0.01) but not further increased by NG-monomethyl-L-arginine
acetate (P=0.2). Insulin potentiated the SNP
response less than the ACh response and the
effect of TNF-alpha was smaller (P<0.001);
TNF-alpha had no effect on the SNP response without
insulin infusion. Thus, TNF-alpha inhibition
of the combined response to insulin and ACh
was likely mediated through inhibition of NO production.
f Conclusion These results
support the concept that TNF-alpha could play
a role in the development of insulin resistance in humans,
both in muscle and in vascular tissue.
- Atherosclerosis
is well-begun preceding the clinical onset of
diabetes (Arteriosclerosis,
Thrombosis, and Vascular Biology [2003] 23:1845) Objective We
examined whether B-mode ultrasounddetected
carotid artery intima-media thickness (IMT)
was elevated before the onset of
clinical diabetes. Methods and
Results The study population for
these analyses included 1127
nondiabetic participants, 66 prediabetic
participants, and 303 diabetic
participants with a mean age of 49.8 years who
participated in the Mexico City Diabetes Study, a
prospective cohort study. Common
carotid artery (CCA) and internal carotid artery
(ICA) IMTs were measured bilaterally by B-mode
ultrasound. Age- and sex-adjusted mean
ICA and CCA IMTs were both significantly higher
among prediabetic individuals {0.81 mm [95%
confidence interval (CI),
0.750.88] and 0.72 mm [95% CI,
0.690.75], respectively} than in
individuals who remained free of diabetes [0.71
mm (95% CI, 0.690.72) and 0.69 mm (95% CI,
0.680.69), respectively].
However, after adjustment for established
cardiovascular risk factors, ICA IMT,
but not CCA IMT, remained significantly higher
among prediabetic individuals [0.81 mm (95% CI,
0.750.88) and 0.71 mm (95% CI,
0.680.74)] than in individuals who remained
free of diabetes [0.71 mm (95% CI,
0.690.72) and 0.69 mm (95% CI,
0.680.70)]. Conclusions
The present study provides direct evidence at
the vascular level that atherosclerosis levels
are elevated before the clinical onset
of diabetes.
Stearoyl-CoA desaturase 1 deficiency
elevates insulin-signaling components and down-regulates
protein-tyrosine phosphatase 1B in muscle (PNAS [2003] 100:11110-11115)
- Macrophage-Specific
p53 Expression Plays a Crucial Role in
Atherosclerosis Development and Plaque Remodeling
(Arteriosclerosis,
Thrombosis, and Vascular Biology [2003]23:1608) Objective We
first showed that absence of p53 accelerates
atherosclerosis development in
apoE-deficient mice. In this study, we
investigated how macrophage-specific loss of p53
function might modulate
atherosclerosis development in LDL
receptor-deficient mice, a model for
familial hypercholesterolemia. Methods
and Results We transferred bone
marrow cells isolated from p53+/+
and p53-/- mice to lethally irradiated
LDL receptor-/- mice and
evaluated the aortic atherosclerotic lesion
areas in the recipients at different times
afterward. At 15 weeks and again at 20
weeks, we found larger aortic lesion size
in mice receiving p53-/- cells
compared with those that received p53+/+
cells. By measuring the rate of bromodeoxyuridine
incorporation, we found that the absence of
p53 in macrophages stimulates cellular
proliferation. In contrast, the rate of apoptosis
in the atheromatous lesion was similar in the two
groups of mice. Furthermore, we found that
the absence of macrophage-specific p53
expression was associated with
vulnerable-appearing lesions marked by
increased tissue necrosis and reduced collagen
deposition. Conclusions
p53 plays a crucial role in atherosclerosis lesion
development and remodeling, and
macrophage-specific p53 deficiency
stimulates cellular proliferation leading to a
vulnerable-appearing phenotype of
lesions in a mouse model of familial
hypercholesterolemia. Key
Words: atherosclerosis apoptosis
proliferation necrosis
macrophage
IGT and DM2
associate with increased arterial stiffness occurring
before the onset of DM2 and explained neither by
conventional CV risk factors nor by hyperglycemia nor by
hyperinsulinemia (Circulation
[2003]107:2089.) Background Type
2 diabetes (DM-2) and impaired glucose metabolism
(IGM) are associated with an increased cardiovascular
disease risk. In nondiabetic individuals, increased
arterial stiffness is an important cause of
cardiovascular disease. Associations between
DM-2 and IGM and arterial stiffness have not been
systematically investigated. Methods
and Results In a population-based cohort
(n=747; 278 with normal glucose metabolism,
168 with IGM, and 301 with DM-2; mean age,
68.5 years), arterial stiffness was ultrasonically estimated
by distensibility and compliance of the carotid, femoral,
and brachial arteries and by the carotid elastic
modulus. After adjustment for age, sex, and
mean arterial pressure, DM-2 was associated
with increased carotid, femoral, and brachial stiffness,
whereas IGM was associated only with increased
femoral and brachial stiffness. Carotid but
not femoral or brachial stiffness increased from
IGM to DM-2. Standardized ßs (95% CI) for IGM and
DM-2, compared with normal glucose metabolism, were -0.06
(-0.23 to 0.10) and -0.37 (-0.51 to -0.23) for
carotid distensibility; -0.02 (-0.18 to 0.18)
and -0.25 (-0.40 to -0.09) for carotid compliance;
-0.05 (-0.23 to 0.13) and 0.25 (0.10 to 0.40) for carotid
elastic modulus; -0.70 (-0.89 to -0.51) and -0.67 (-0.83
to -0.52) for femoral distensibility; and -0.62
(-0.80 to -0.44) and -0.79 (-0.94 to -0.63)
for femoral compliance. The brachial artery
followed a pattern similar to that of the femoral artery.
Increases in stiffness indices were explained by
decreases in distension, increases in pulse
pressure, an increase in carotid intima-media
thickness, and, for the femoral artery, a decrease in
diameter. Hyperglycemia or hyperinsulinemia explained
only 30% of the arterial changes associated
with glucose tolerance. Adjustment for
conventional cardiovascular risk factors did not
affect these findings. Conclusions
IGM and DM-2 are associated with increased arterial
stiffness. An important part of the increased stiffness
occurs before the onset of DM-2 and is explained
neither by conventional cardiovascular risk
factors nor by hyperglycemia or
hyperinsulinemia.
- In-hospital
LVF and cardiac mortality imply admission
glycemia in ACS [independent of diabetic status] (Heart [2003] 24:309-321) Objectives: To analyse the
relation between serum glucose concentration
and hospital outcome across the whole
spectrum of acute coronary syndromes.
Methods: This was a prospective
cohort study of 2127 patients presenting
with acute coronary syndromes. The patients were
stratified into quartile groups (Q1 to Q4)
defined by serum glucose
concentrations of 5.8, 7.2, and 10.0 mmol/l. The
relation between quartile group and
major in-hospital complications was analysed.
Results: The proportion of patients
with acute myocardial infarction increased
incrementally across the quartile groups, from
21.4% in Q1 to 47.9% in Q4 (p <
0.0001). The trend for frequency of
in-hospital major complications was similar,
particularly left ventricular failure
(LVF) (Q1 6.4%, Q4 25.2%, p < 0.0001) and
cardiac death (Q1 0.7%, Q4 6.1%, p < 0.0001).
The relations were linear, each
glucose quartile increment being associated with
an odds ratio of 1.46 (95% confidence interval
(CI) 1.27 to 1.70) for LVF and 1.52
(95% CI 1.17 to 1.97) for cardiac death.
Although complication rates were higher for a
discharge diagnosis of acute
myocardial infarction than for unstable angina,
there was no evidence that the effects of
serum glucose concentration were
different for the two groups, there being no
significant interaction with discharge
diagnosis in the associations between glucose
quartile and LVF (p = 0.69) or cardiac death (p =
0.17). Similarly there was no
significant interaction with diabetic status
in the associations between glucose quartile and
LVF (p = 0.08) or cardiac death (p =
0.09). Conclusion: Admission
glycaemia stratified patients with acute coronary
syndromes according to their risk of in-hospital
LVF and cardiac mortality. There was
no detectable glycaemic threshold for
these adverse effects. The prognostic correlates
of admission glycaemia were unaffected
by diabetic status and did not differ significantly
between patients with acute myocardial infarction
and those with unstable angina.
S447X (serine)
substitution on lipoprotein lipase (LPL) gene associates
frequently with a high-HDL/low-LDL phenotype and
infrequently with a low-HDL/high-LDL phenotype (Genetic Epidemiology
[2003] 24:309-321) S447X,
a serine substitution by a stop codon on base 99 of exon
9 of the lipoprotein lipase (LPL) gene, has beneficial
effects on blood lipids. Other LPL alleles are associated
with lipid levels, but whether one of these variants
predominates remains elusive. We performed a systematic
survey to identify single-nucleotide polymorphisms (SNPs)
in all 10 LPL exons and flanking regions by resequencing
the gene in 95 subjects. Of 24 variants, 14 were common
(>=3%). We assayed the common SNPs in 186 cases with
atherogenic lipid profiles (low HDL, high LDL) and 185
nonatherogenic controls (high HDL, low LDL). Only S447X
and exons 6 (base +73) and 10 (base -11) were
individually associated with case-control status (P<0.05,
adjusted for major nongenetic covariates with known lipid
effects). There were no significant SNP×gender
interactions. In adjusted multi-SNP and haplotypic
analyses, S447X was interpretable as the sole predictor,
with a 2-3-fold reduction in the odds of being
atherogenic vs. nonatherogenic (adjusted OR, 0.39; 95%
CI, 0.21-0.73). S447X and base -11 of exon 10 were
statistically interchangeable because they are strongly
associated (r=0.92, P<0.0001), but we posit
that the LPL association with lipid profile is more
likely attributable to the functional S447X rather than
the nonfunctional exon 10 SNP. It appears that the S447X
variant of LPL may be another rare example (like APOE4,
factor V-Leiden, and PPAR-gamma Pro12Ala) of a common
variant predisposing to a common disorder
- Fasting
glucose levels appear to increase in dysmetabolic
hypertensive patients who develop MI and to
decrease in normotensives who do not (BMJ [2003] 326:681)
Objective:
To investigate the impact of an increase in blood
glucose on the risk of developing myocardial
infarction, with particular emphasis
on people taking antihypertensive drugs.
Design: Prospective population based
cohort study. Setting: Uppsala,
Sweden. Participants: 1860 men who
had participated in 1970-3 at age
50 in a health survey aimed at identifying
risk factors for cardiovascular
disease and were re-examined at age 60 and
then followed for 17.4 years.
Main outcome measure: Myocardial
infarction after age 60. Results:
The incidence of myocardial infarction was significantly
higher in men treated for hypertension than in
those without such treatment (23% v
13.5%, P<0.0001). Participants who developed
myocardial infarction after the age of
60 (n=253) showed a significantly
larger increase in blood glucose between age 50 and
60 than did those without myocardial
infarction. In multivariate Cox
proportional hazard models increase in blood
glucose was an independent risk factor
for myocardial infarction (P=0.0001) in men
receiving antihypertensive treatment at age
60 (n=291, mainly beta- blockers
and thiazide diuretics) but not in those without
such treatment. The impact of increase
in blood glucose declined after inclusion
of serum proinsulin concentrations at baseline
but was still significant. A
significant interaction existed between
proinsulin concentration (a marker of
insulin resistance) at baseline and antihypertensive
treatment on increase in blood glucose.
Conclusions: Increase in blood glucose
between the ages of 50 and
60 and baseline proinsulin concentration
were important risk factors for
myocardial infarction in men receiving
antihypertensive treatment, indicating
that both an insulin resistant state and the
metabolic impact of beta- blockers and
diuretics increase the risk of
myocardial infarction.
Antileukotriene
drugs may be an effective treatment regimen in late-stage
atherogenesis (Proc.
Natl. Acad. Sci. USA, [2003] 10.1073/pnas.242716099) Oxidation
products of low-density lipoproteins have been
suggested to promote inflammation during
atherogenesis, and reticulocyte-type 15-lipoxygenase
has been implicated to mediate this oxidation. In
addition, the 5-lipoxygenase cascade leads to formation
of leukotrienes, which exhibit strong
proinflammatory activities in cardiovascular
tissues. Here, we studied both lipoxygenase pathways
in human atherosclerosis. The 5-lipoxygenase pathway
was abundantly expressed in arterial walls of
patients afflicted with various lesion stages
of atherosclerosis of the aorta and of
coronary and carotid arteries. 5-lipoxygenase localized
to macrophages, dendritic cells, foam cells,
mast cells, and neutrophilic granulocytes, and
the number of 5-lipoxygenase expressing cells markedly
increased in advanced lesions. By contrast,
reticulocyte-type 15-lipoxygenase was
expressed at levels that were several orders of
magnitude lower than 5-lipoxygenase in both normal and
diseased arteries, and its expression could
not be related to lesion pathology. Our data
support a model of atherogenesis in which 5-lipoxygenase
cascade-dependent inflammatory circuits consisting of
several leukocyte lineages and arterial wall cells evolve
within the blood vessel wall during critical stages
of lesion development. They raise the
possibility that antileukotriene drugs may be
an effective treatment regimen in late-stage disease.
- Diabetic Macrovascular Disease -The
Glucose Paradox? (Circulation.
2002;106:2760) -editorial by Peter Libby The specific interventions
used to lower glycemia may contribute to
the inability to show decreases in macrovascular
end points. With some antidiabetic
treatments, untoward effects may counterbalance
potential benefits. Generally,
interventions that increase insulin supply
(eg, insulin itself and sulfonylureas) have
proven less promising for limiting
cardiovascular complications than those that
improve glucose utilization or reduce insulin
resistance. Indeed, in one arm of
UKPDS, metformin monotherapy decreased MI
by 39% (P0.01) in an
overweight subgroup, a benefit not seen in
patients requiring metformin plus sulfonylureas
or insulin. Thiazolidinediones (the
"glitazones") hold considerable promise
as insulin sensitizers and merit careful
clinical evaluation for cardiovascular
benefit.
Elevated
levels of acute-phase proteins and plasminogen activator
inhibitor-1 predict the development of type 2 diabetes:
the insulin resistance atherosclerosis study.(Diabetes 2002 Apr;51(4):1131-7) Festa A, D'Agostino R Jr, Tracy
RP, Haffner SM; The Insulin Resistance Atherosclerosis
Study.Elevated serum levels of acute-phase proteins,
indicating chronic subclinical inflammation, have been
associated with cardiovascular disease as well as the
insulin resistance syndrome. Chronic inflammation may
also be a risk factor for developing type 2 diabetes. We
studied the concentrations of C-reactive protein (CRP),
fibrinogen, and plasminogen activator inhibitor-1 (PAI-1)
in 1,047 nondiabetic subjects in relation to incident
diabetes within 5 years in the Insulin Resistance
Atherosclerosis Study. Subjects with diabetes at
follow-up (n = 144) had higher baseline levels of
fibrinogen (mean +/- SD; 287.8 +/- 58.8 vs. 275.1 +/-
56.0 mg/dl; P = 0.013) as well as of CRP (median
[interquartile range]; 2.40 [1.29, 5.87] vs. 1.67 mg/l
[0.75, 3.41]; P = 0.0001) and PAI-1 (24 [15, 37.5] vs. 16
ng/ml [9, 27]; P = 0.0001) than nonconverters. The odds
ratio (OR) of converting to diabetes was significantly
increased with increasing baseline concentrations of the
inflammatory markers. In contrast to PAI-1, the
association of CRP and fibrinogen with incident diabetes
was significantly attenuated after adjustment for body
fat (BMI or waist circumference) or insulin sensitivity
(S(I)), as assessed by a frequently sampled intravenous
glucose tolerance test. In a logistic regression model
that included age, sex, ethnicity, clinical center,
smoking, BMI, S(I), physical activity, and family history
of diabetes, PAI-1 still remained significantly related
to incident type 2 diabetes (OR [95% CI] for 1 SD
increase: 1.61 [1.20-2.16]; P = 0.002). Chronic
inflammation emerges as a new risk factor for the
development of type 2 diabetes; PAI-1 predicts type 2
diabetes independent of insulin resistance and other
known risk factors for diabetes.
- Depolarization
of Endothelial Cells Enhances Platelet
Aggregation Through Oxidative Inactivation of
Endothelial NTPDase (Arteriosclerosis,
Thrombosis, and Vascular Biology 2002, 10.1161/01)
Objective:
The objective of this study was to investigate
whether depolarization of cultured endothelial
cells (human umbilical vein endothelial cells,
HUVECs) affects their ectonucleotidase activity
through superoxide (O2-) production. Methods
and ResultsDepolarization by the
cation channel gramicidin (100 nmol/L) or
tetrabutylammonium chloride (1 mmol/L) induced
O2- release from HUVECs (n=4), which was
decreased by superoxide dismutase (SOD, 500
U/mL). The activity of endothelial
ectonucleotidases was assessed by the production
of inorganic phosphate from ADP, which was
decreased by chronic depolarization by 25% (n=6,
P<0.05) and the amount of AMP derived from ADP
in the presence of the 5'-nucleotidase inhibitor
,ß-methylene-5'-diphosphate (00 µmol/L). AMP
was decreased by chronic depolarization from
0.54±0.16 to 0.39±0.11 µmol/min/mg protein
(n=6, P<0.05). This was abolished in the
continuous presence of SOD (n=6). NTPDase protein
was predominantly expressed in HUVECs (n=4).
Protein abundance, viability of cells, and
apoptosis rates were not altered by
depolarization (n=10). Only in the presence of
depolarized HUVECs, but not with control cells or
with HUVECs depolarized in the presence of SOD,
did 5 µmol/L of ADP cause irreversible platelet
aggregation. Increases in transmural pressure
induced endothelial depolarization in intact
hamster small arterioles. ConclusionsDepolarization
causes the endothelial production of O2-, which
inhibits the activity of endothelial
ectonucleotidases. Increases in transmural
pressure induce endothelial depolarization. In
chronically hypertensive diseases, depolarization
might favor platelet aggregation.
Nutritionally
Induced Obesity Is Attenuated in Transgenic Mice
Overexpressing Plasminogen Activator Inhibitor-1 (Arteriosclerosis, Thrombosis, and Vascular
Biology 2002) ObjectiveThe objective of
this study was to investigate the role of plasminogen
activator inhibitor-1 (PAI-1) in adipose tissue
development in vivo. Methods and ResultsTransgenic
(Tg) mice overexpressing murine PAI-1 under control of
the adipocyte promoter aP2 and wild-type (WT) controls
were kept on standard food (SFD) or on high-fat diet
(HFD) for 15 weeks. The body weight and the weight of the
isolated subcuttaneus and gonadal fat deposits of the Tg
mice kept on the HFD were significantly lower than those
of the WT mice. The number of adipocytes in the adipose
tissue was similar for Tg and WT mice on the HFD, but
adipocyte hypotrophy and a significantly lower ratio of
stroma cells/adipocytes were observed in the Tg mice. A
significant negative correlation (P<0.01) was observed
between expression of preadipocyte factor-1, which blocks
adipocyte differentiation, and adipose tissue weight.
Fasting insulin and total cholesterol levels on the HFD
were lower in Tg than in WT mice. ConclusionsHigh
circulating PAI-1 levels attenuate nutritionally induced
obesity. This may be related to modifications in adipose
tissue cellularity affecting weight and plasma metabolic
parameters.
- Increased
apoA-I catabolism is found in dysmetabolic women
and is consistent with the increased risk of
atherosclerosis in this population. (Int J
Obes Relat Metab Disord [2002] Sep;26(9):1151-8) Pont f , Duvillard l , Florentin e ,
Gambert p , Verges b AIMS/HYPOTHESIS: Mechanisms
responsible for the decreased high-density
lipoprotein (HDL) cholesterol level associated
with insulin resistance in obese patients are not
clearly understood. To determine the influence of
insulin resistance at an early stage on HDL
metabolism, we performed a stable isotope kinetic
study of apolipoprotein (apo) A-I, in five obese
insulin resistant women with normal fasting
triglycerides and without impaired glucose
tolerance, and in five age-matched control women.
METHODS: Each subject received a 16 h constant
infusion of L-[1-(13)C]leucine at 0.7 mg/kg/h
following a primed bolus of 0.7 mg/kg. RESULTS:
ApoA-I fractional catabolic rate (FCR) was
significantly increased in insulin-resistantTan
en compared to controls (0.316+/-0.056 vs
0.210+/-0.040 per day, P<0.01), indicating a
significant 50% increase of apoA-I catabolism,
leading to an important Tan ction of plasma
apoA-I residence time (3.25+/-0.59 vs
4.92+/-1.11, P<0.01). ApoA-I production rate
tended to be higher in insulin resistant wTan
than in controls (364+/-77 vs 258+/-60 mg/l/day,
P=0.13), but the difference was not statistically
significant. ApoA-I FCR was correlated with
triglycerides during the fed state (r=0.69;
P=0.026) and HDL triglycerides-esterified
cholesterol ratio (r=0.73; P=0.016), suggesting
that alteration of apoA-I metabolism in insulin
resistance mTan e partly related to HDL
enrichment in triglycerides. CONCLUSIONS: Our
kinetic study shows that patients, at an early
stage of insulin resistance (without impaired
glucose tolerance nor fasting
hypertriglyceridaemia), already have a
significant alteration of apoA-I metabolism
(increased apoA-I catabolism), which is
consistent with the increased risk of
atherosclerosis in this population.
Serum
homocysteine, creatinine, and glucose are predictors of
the severity and extent of
coronary artery disease in asymptomatic members of
high-risk families (Eur J Clin Invest [2002] 32:472)
Pajunen P , Syvänne
Mikko , Nieminen M S, Kareinen Anu , Viitanen Laura ,
Lehto Seppo , Laakso Markku Background There has been no
previous study to determine the severity and extent of
coronary artery disease (CAD) in subjects with no
diagnosis or symptoms of CAD at the time of the
angiography. Methods Fifty-three subjects, who were
siblings of patients with early onset CAD, underwent
coronary angiography. Indices to describe per-patient
characteristics of CAD were calculated, based on
computer-aided quantitative coronary angiography.
Clinical and laboratory characteristics were correlated
to the angiographic parameters. ResultsSerum total
homocysteine ( = 0·29, P < 0·05) and creatinine ( =
0·47, P = 0·001) levels were related to the global
atheroma burden index. The median of the atheroma burden
index was two times higher in the top homocysteine
quartile compared to the lowest quartile. The overall
atheroma burden index correlated significantly with the
fasting blood glucose level in all subjects. Diabetes,
especially when albuminuria was present, was a powerful
risk factor. In a multivariate analysis, only age and sex
were independent predictors of atheroma burden.
ConclusionsSerum homocysteine and creatinine
concentrations, and diabetes with albuminuria were found
to be markers of the severity and extent of CAD in
subjects of high-risk families without symptoms of CAD.
- Unsaturated
fatty acids and their oxidation products
stimulate CD36 gene expression in human
macrophages (Atherosclerosis
[2002] 164:45-56) Fatty acids (FA) have been
implicated in the control of expression of
several atherosclerosis-related genes. Similarly,
the CD36 receptor has recently been shown to play
an important role in atherosclerosis and other
pathologies. The aim of the present study was to
evaluate the direct effect of FA and their
oxidation products (aldehydes), on the expression
of CD36 in both THP-1 macrophages and human
monocyte-derived macrophages (HMDM). The FA
tested included the saturated FA (SFA) lauric,
myristic, palmitic and stearic acid; the
monounsaturated FA oleic acid; and the
unsaturated FA (UFA) linoleic, arachidonic acid
(AA), eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). Aldehydes used were
malondialdehyde (MDA), hexanal, 2,4-decadienal
(DDE) and 4-hydroxynonenal (HNE). CD36 expression
was measured by RT-PCR, Western blot and
immunofluorescence. Incubation of THP-1
macrophages for 24 h with non-cytotoxic
concentrations of UFA significantly increased
CD36 mRNA expression. By contrast, exposure of
THP-1 macrophages to SFA did not affect the
levels of CD36 mRNA. Among all UFAs tested, EPA
and DHA were the strongest inducers of CD36 mRNA
levels, followed by oleic and linoleic acid.
Incubation of HMDM with either oleic or linoleic
acid significantly increased steady-state CD36
mRNA in a dose-dependent manner. Consistent with
the increase of CD36 mRNA expression, incubation
of THP-1 macrophages with oleic and linoleic acid
for 24 h markedly increased CD36 protein
expression. Treatment of THP-1 macrophages with
MDA or hexanal for 24 h significantly increased
CD36 mRNA expression in a dose dependent manner.
In contrast, DDE and HNE significantly decreased
this parameter. The data provide evidence for a
direct regulatory effect of UFA on CD36 gene
expression and support a role for aldehydes in
the regulation of CD36 expression by FA.
Fasting and
postchallenge hyperglycaemia in the early phase of an
acute myocardial infarction could be used as early
markers of high-risk individuals (Lancet [2002] 359:
2140-44)Background Glycometabolic state at
hospital admission is an important risk marker for
long-term mortality in patients with acute myocardial
infarction, whether or not they have known diabetes
mellitus. Our aim was to ascertain the prevalence of
impaired glucose metabolism in patients without diagnosed
diabetes but with myocardial infarction, and to assess
whether such abnormalities can be identified in the early
course of a myocardial infarction. Methods We did
a prospective study, in which we enrolled 181 consecutive
patients admitted to the coronary care units of two
hospitals in Sweden with acute myocardial infarction, no
diagnosis of diabetes, and a blood glucose concentration
of less than 11·1 mmol/L. We recorded glucose
concentrations during the hospital stay, and did
standardised oral glucose tolerance tests with 75 g of
glucose at discharge and again 3 months later. Findings
The mean age of our cohort was 63·5 years (SD 9) and
the mean blood glucose concentration at admission was
6·5 mmol/L (1·4). The mean 2-h postload blood glucose
concentration was 9·2 mmol/L (2·9) at hospital
discharge, and 9·0 mmol/L (3·0) 3 months later. 58 of
164 (35%, 95% CI 28-43) and 58 of 144 (40%, 32-48)
individuals had impaired glucose tolerance at discharge
and after 3 months, respectively, and 51 of 164 (31%,
24-38) and 36 of 144 (25%, 18-32) had previously
undiagnosed diabetes mellitus. Independent predictors of
abnormal glucose tolerance at 3 months were
concentrations of HbA1c at admission
(p=0·024) and fasting blood glucose concentrations on
day 4 (p=0·044). Interpretation Previously
undiagnosed diabetes and impaired glucose tolerance are
common in patients with an acute myocardial infarction.
These abnormalities can be detected early in the
postinfarction period. Our results suggest that fasting
and postchallenge hyperglycaemia in the early phase of an
acute myocardial infarction could be used as early
markers of high-risk individuals.
- Interleukin-18
Is a Strong Predictor of Cardiovascular Death in
Stable and Unstable Angina (Circulation [2002]106:24) Background
Interleukin (IL)-18 plays a central role in orchestrating
the cytokine cascade and accelerates
atherosclerosis and plaque
vulnerability in animal models. However,
epidemiological data evaluating the
role of IL-18 levels in atherosclerosis are
lacking. M ethods
and Results In a prospective study
of 1229 patients with documented
coronary artery disease, we measured
baselinemarkers of serum concentrations of IL-18
and other inflammation. During the
follow-up period (median, 3.9 years), 95 patients
died of cardiovascular causes. Median serum
concentrations of IL-18 were
significantly higher among patients who had a
fatal cardiovascular event than among
those who did not (68.4 versus 58.7
pg/mL; P<0.0001). The hazard risk ratio
of future cardiovascular death
increased with increasing quartiles of IL-18
(hazard risk ratio, 1.46; 95% CI 1.21
to 1.76; P for trend <0.0001). After
adjustment for most potential confounders,
including the strong predictor
ejection fraction as well as the inflammatory
variables IL-6, high-sensitive
C-reactive protein, and fibrinogen, this relation
remained almost unchanged, such that patients
within the highest quartile of IL-18
had a 3.3-fold increase in hazard risk
compared with those in the first quartile (95%
CI, 1.3 to 8.4, P=0.01). This
relation was observed in patients with stable
angina and patients with unstable angina at
baseline. Conclusions
Serum IL-18 level was identified as a strong
independent predictor of death from
cardiovascular causes in patients with
coronary artery disease regardless of the
clinical status at admission. This
result strongly supports recent experimental
evidence of IL-18mediated
inflammation leading to acceleration and
vulnerability of atherosclerotic plaques.
Ang II
provokes TNF biosynthesis in the adult mammalian heart
through a PKC-dependent pathway. (Circulation [2002] 105:2198.)Background
Previous studies suggest that angiotensin II
(Ang II) upregulates the expression of tumor necrosis
factor (TNF) in nonmyocyte cell types;
however, the effect of Ang II on TNF
expression in the adult mammalian heart is not known.
Methods and Results To
determine whether Ang II was sufficient to
provoke TNF biosynthesis in the adult heart, we examined
the effects of Ang II in isolated buffer-perfused
Langendorff feline hearts. Ang II (10-7
mol/L) treatment resulted in a time- and
dose-dependent increase in myocardial TNF mRNA and
protein biosynthesis in the heart as well as
in cultured adult cardiac myocytes. The
effects of Ang II on myocardial TNF mRNA and protein
synthesis were mediated through the angiotensin
type 1 receptor (AT1R), insofar as
an AT1R antagonist (AT1a) blocked
the effects of Ang II, whereas an angiotensin
type 2 receptor (AT2R) antagonist (AT2a)
had no effect. Stimulation with Ang II led to the
activation of nuclear factor-kappaB and
activator protein-1 (AP-1), two transcription factors
that are important for TNF gene expression. Nuclear factor-kappa-B-alpha activation was accompanied by
phosphorylation of Ikappa Balpha on serine 32 as
well as degradation of IkappaB-alpha,
suggesting that the effects of Ang II were
mediated through an IkappaBalpha-dependent pathway. The
important role of protein kinase C (PKC) was suggested by
studies in which a phorbol ester triggered TNF
biosynthesis, and a PKC inhibitor abrogated
Ang IIinduced TNF biosynthesis. Conclusions
These studies suggest that Ang II provokes TNF
biosynthesis in the adult mammalian heart through a
PKC-dependent pathway.
- Proinsulin
Is an Independent Predictor of Coronary Heart
Disease (Circulation
[2002] 105:2153) Background
Some, but not all, studies have reported a relationship
between plasma insulin and coronary heart disease
(CHD). Conventional nonspecific insulin
assays are also measuring various
fractions of proinsulin-like molecules due to
cross-reactivity. The long-term
relationship between proinsulin-like molecules
and CHD is largely unknown. For this
reason, the longitudinal relationships
between intact proinsulin, split proinsulin,
specific insulin, immunoreactive
insulin, and CHD, were studied in a population-based
cohort of 50-year-old men (n=874), with a
follow-up of 27 years. Methods
and Results Fasting proinsulin-like
molecule and specific-insulin
concentrations were measured in plasma (stored
frozen since baseline 1970 to 1973) by specific
2-site immunometric assays.
Immunoreactive insulin concentrations were determined
at baseline. The associations between
proinsulin-like molecules, specific
insulin, immunoreactive insulin, and CHD mortality
(International Classification of Diseases [9th
revision] codes 410 to 414) were
analyzed using Coxs proportional hazards
regression and presented as hazard ratios (HRs)
with their 95% confidence intervals
(CIs) for a 1-SD increase in a
predictor variable. In the univariate analysis,
intact proinsulin (HR, 1.69; 95% CI,
1.41 to 2.01) was the strongest predictor of
death from CHD. In the multivariate analysis,
smoking (HR, 1.57; 95% CI, 1.03 to
2.38), intact proinsulin (HR, 1.47; 95% CI,
1.18 to 1.82), systolic blood pressure (HR, 1.38;
95% CI, 1.14 to 1.66), and LDL/HDL
cholesterol ratio (HR, 1.31; 95% CI,
1.12 to 1.53) were independent predictors of CHD
mortality (adjusted for body mass
index, triglycerides, and fasting glucose), whereas
specific insulin and immunoreactive insulin were
not (HR, 1.12; 95% CI, 0.90 to 1.40).
The increased risk was restricted to
the upper third of the proinsulin distribution.
Conclusion Increased
proinsulin concentrations predict death
and morbidity caused by CHD over a period of 27
years, independent of other major
cardiovascular risk factors
Atrial
Natriuretic Peptide Reduces TNF-Induced Actin
Polymerization and Endothelial Permeability (Circulation Research
[2002]90:874) The atrial natriuretic peptide
(ANP) is a cardiovascular hormone possessing
antiinflammatory potential due to its inhibitory action
on the production of inflammatory mediators, such as
tumor necrosis factor-alpha (TNF-alpha). The aim of this
study was to determine whether ANP is able to attenuate
inflammatory effects of TNF-alpha on target cells. Human
umbilical vein endothelial cells (HUVECs) were treated
with TNF-alpha in the presence or absence of ANP. Changes
in permeability, cytoskeletal alterations,
phosphorylation of p38 MAPK and HSP27, and expression of
MKP-1 were determined by macromolecule permeability
assay, fluorescence labeling, RT-PCR, and immunoblotting.
Antisense studies were done by transfecting cells with
MKP-1 antisense oligonucleotides. Activation of HUVECs
with TNF-alpha lead to a significant increase of
macromolecule permeability and formation of stress
fibers. Treatment of cells with ANP (10(-8) to 10(-6)
mol/L) significantly reduced the formation of stress
fibers and elevated permeability. Both TNF-alpha-induced
effects were shown to be mediated via the activation of
p38 using SB203580, a specific inhibitor of p38. ANP
significantly reduced the TNF-alpha-induced activation of
p38 and attenuated the phosphorylation of HSP27, a
central target downstream of p38. ANP showed no effect on
p38 upstream kinases MKK3/6. However, a significant
induction of the MAPK phosphatase MKP-1 mRNA and protein
could be observed in ANP-treated cells. Antisense
experiments proved a causal role for MKP-1 induction in
the ANP-mediated inhibition of p38. These data show the
inhibitory action of ANP on TNF-alpha-induced changes in
endothelial cytoskeleton and macromolecule permeability
involving an MKP-1-induced inactivation of p38 MAPK.
These effects point to an antiinflammatory and
antiatherogenic potential of this cardiovascular hormone.
- The
Kir6.1-containing K+ channel is critical in the
regulation of vascular tonus, especially in the
coronary arteries, and its disruption may cause
Prinzmetal angina. (Nature Med [2002] 8:466-472) The inwardly rectifying K+
channel Kir6.1 forms K+ channels by
coupling with a sulfonylurea receptor in
reconstituted systems, but the physiological
roles of Kir6.1-containing K+ channels
have not been determined. We report here that
mice lacking the gene encoding Kir6.1 (known as Kcnj8)
have a high rate of sudden death associated with
spontaneous ST elevation followed by
atrioventricular block as seen on an
electrocardiogram. The K+ channel
opener pinacidil did not induce K+
currents in vascular smooth-muscle cells of
Kir6.1-null mice, and there was no vasodilation
response to pinacidil. The administration of
methylergometrine, a vasoconstrictive agent,
elicited ST elevation followed by cardiac death
in Kir6.1-null mice but not in wild-type mice,
indicating a phenotype characterized by
hypercontractility of coronary arteries and
resembling Prinzmetal (or variant) angina in
humans. The Kir6.1-containing K+
channel is critical in the regulation of vascular
tonus, especially in the coronary arteries, and
its disruption may cause Prinzmetal angina.
Insulin
resistance in moderate chronic heart failure is related
to hyperleptinaemia, but not to norepinephrine or
TNF-alpha (International
Journal of Cardiology [2002] 83:73-81) Objectives:
Chronic heart failure (CHF) has emerged as an
insulin-resistant state, independently of ischaemic
aetiology. The underlying mechanisms of this finding are
not known. Catecholamines, tumor necrosis factor alpha
(TNF) and leptin, the adipocyte
specific hormone, have all been implicated as mediators
of impaired insulin sensitivity. The purpose of this
study was to examine in patients with CHF and in
comparison to healthy controls subjects whether
norepinephrine, TNF or leptin relate to insulin
sensitivity. Design: 41 patients with CHF (age
60±2 years, NYHA I/II/III/IV 4/12/22/3, peak oxygen
consumption 17.6±1.0 ml/kg per min) and 21 healthy
controls of similar age and total and regional fat
distribution were studied in a cross-sectional study.
Insulin sensitivity was assessed by intravenous glucose
tolerance testing using the minimal model approach;
catecholamines, TNF and soluble TNF receptors 1 and 2
were also measured. Total and regional body fat mass was
assessed by dual energy X-ray absorptiometry. Results:
Insulin sensitivity was reduced in CHF patients compared
to controls by 31% (P<0.01) and fasting insulin
was higher in patients than in controls (79.1±9.7 vs.
41.4±6.0 pmol/l, P<0.01). Patients had,
compared to healthy controls, elevated serum leptin
levels (8.28±0.84 vs. 4.83±0.68 ng/ml), norepinephrine
(3.45±0.34 vs. 1.87±0.16 nmol/l, both P<0.01)
and soluble TNF-receptors 1 (1280±141 vs. 639±52 pg/ml)
and 2 (2605±184 vs. 1758±221 pg/ml, both P<0.01).
Leptin levels corrected for total body fat mass were
higher in CHF patients than in controls (41.3±3 vs.
24.3±2 pg/ml per 100 g, P<0.001). TNF was not significantly different
between the groups. In both groups there was an inverse
correlation between insulin sensitivity and serum leptin
(r=-0.65, P<0.0001 for pooled subjects);
in contrast, no significant relation was found between
insulin sensitivity and norepinephrine or TNF. In multivariate regression
analysis, leptin emerged as the only significant
predictor of insulin sensitivity (standardised
COEFFICIENT=-0.59, P<0.001), independent of
body fat mass, age and peak V2.
Conclusion: In moderate CHF, elevated leptin
levels directly and independently predict insulin
resistance. Elevated serum leptin levels could play a
role in the impaired regulation of energy metabolism in
CHF. In contrast to observations in other conditions, TNF and norepinephrine are not related
to insulin resistance in moderate CHF.
- Leptin
contributes to arterial thrombosis following
vascular injury in vivo (JAMA. [2002] 287:1706-1709) Context Complications
of atherosclerosis are the leading cause of
morbidity and mortality in industrialized
societies. Obesity has emerged as an independent
risk factor for complications of atherosclerotic
vascular disease. Leptin, a hormone produced by
the adipocyte, increases with obesity and appears
to modulate energy balance and food intake. In
addition, other actions of leptin have been
proposed, including an in vitro effect on
platelet aggregation. Thus, the elevated plasma
leptin levels in obese individuals may promote
vascular thrombosis. Objective To
test the hypothesis that leptin contributes to in
vivo thrombosis via the leptin receptor. Design
and Materials Between September
2000 and September 2001, a vascular thrombosis
model was used to test male 10- to 12-week-old
mice completely deficient in leptin or the leptin
receptor and mice with platelet leptin-receptor
deficiency. Main Outcome Measure Time
to formation of an occlusive thrombus in the
common carotid artery following experimentally
induced endothelial injury. Results Following
onset of vascular injury, wild-type mice (n = 8)
formed occlusive thrombosis in a mean (SD) of
42.2 (4.6) minutes, whereas leptin-deficient (n =
5) and leptin receptordeficient mice (n =
7) formed occlusive thrombosis in 75.2 (10.1) and
68.6 (10.3) minutes, respectively (leptin
deficient vs wild-type mice, P = .008;
leptin-receptordeficient vs wild-type, P
= .03). When recombinant murine leptin was
administered to leptin-deficient mice (n = 4),
the time to occlusion was reduced to 41.8 (6.6)
minutes (P = .035 vs vehicle control).
Following bone marrow transplantation from leptin
receptordeficient (donor) mice to wild-type
(recipient) mice, the time to occlusion was
prolonged from 22.3 (2.8) minutes in wild-type
mice receiving wild-type marrow (n = 3) to 56.8
(5.0) minutes in wild-type mice receiving leptin
receptordeficient bone marrow (n = 5) (P
= .003). Conclusions Leptin
contributes to arterial thrombosis following
vascular injury in vivo and these prothrombotic
effects appear to be mediated through the
platelet leptin receptor.
Increased Serum
Levels of Macrophage Migration Inhibitory Factor-Related
Protein Is a Sensitive Marker for Acute Coronary Syndrome
in Patients With Coronary Artery Disease (ACC 2002) BACKGROUND:
In patients with coronary artery disease (CAD), it is
important to discriminate acute coronary syndrome (ACS).
There is accumulating data that ACS relates to recent
activation of inflammation affecting atherosclerotic
plaques. Macrophage migration inhibitory factor-related
protein (MRP) is a calcium-binding protein (heterodimer),
which is expressed in infiltrate macrophages during
inflammatory reactions. The purpose of this study was to
investigate whether MRP is useful for the diagnosis of
ACS. Methods: We studied 92 patients with
angiographically proven CAD. They comprised two groups
[Group ACS, Braunwald's subclass II or III of unstable
angina, and acute myocardial infarction, n=53; Group SA,
stable angina, n=39]. We purified MRP from human
leukocytes and then prepared rabbit monoclonal antibodies
against the MRP. Serum concentrations of MRP were
measured using a newly-developed enzyme-linked
immunosorbent assay system. In addition, we measured
serum concentrations of C-reactive protein (CRP).
RESULTS: There were no significant differences in age,
gender and coronary risk factors between the two groups.
Serum MRP levels were significantly higher in Group ACS
than in Group SA [3.25±3.08 (SD) microgram/ml vs.
0.77±0.31 microgram/ml, p < 0.0001]. Serum CRP levels
were also significantly higher in Group ACS than in Group
SA (3.11±6.14 mg/dl vs. 0.19±0.20 mg/dl, p=0.0039).
Sensitivity and specificity of positive serum MRP levels
(> 1.2 microgram/ml) for detection of ACS were 84.9%
and 89.7%, respectively. On the other hand, sensitivity
and specificity of positive serum CRP levels (>
0.5mg/dl) for detection of ACS were 52.8% and 92.3%,
respectively. Sensitivity was significantly (p < 0.05)
higher in the measurements of MRP than in the
measurements of CRP, while specificity was comparable in
the two markers. Conclusion: The measurement of serum MRP
levels is useful for the discrimination of ACS in
patients with CAD.
- High
fibrinogen levels associated with high Lp(a)
levels significantly increases the risk of CHD. (Am J Cardiol [2002]
89:662-666)Fibrinogen has been
prospectively found to correlate with coronary
heart disease (CHD) but a similar association has
not been well established for lipoprotein (a)
(Lp(a)). Plasma lipids, Lp(a), and fibrinogen
levels were measured in 2,125 men (aged 47 to 76
years) who were free of clinical CHD. During a
5-year follow-up period, 116 first CHD events
were documented. Men with CHD were older, smoked
more, had a higher prevalence of diabetes, and
higher levels of systolic blood pressure,
cholesterol, low-density lipoprotein cholesterol,
Lp(a), and fibrinogen, and lower plasma
high-density lipoprotein cholesterol levels. Only
fibrinogen levels in the upper tertile of the
distribution compared with the lower tertiles
were associated with a significant risk of CHD
(adjusted risk ratio 2.5; 95% confidence interval
[CI] 1.4 to 4.2; P = 0.0010). Such an association
was not observed with Lp(a). To assess a possible
relation between fibrinogen and Lp(a) to the risk
of CHD events, men were assigned to 1 of 4 groups
according to fibrinogen median levels and a Lp(a)
cut-off level of 300 mg/L: group 1: fibrinogen
<4.05 g/L and Lp(a) <300 mg/L; group 2:
fibrinogen <4.05 g/L and Lp(a) 300 mg/L; group 3:
fibrinogen 4.05 g/L and Lp(a) <300
mg/L; and group 4: fibrinogen 4.05 g/L and Lp(a) 300 mg/L. Using group 1 as
a reference, a significant risk ratio was only
documented in group 4 (2.5; 95% CI 1.2 to 5.1; P
= 0.0132). In this population, high fibrinogen
levels associated with high Lp(a) levels
significantly increased the risk of CHD
Patients with
chronic heart failure exhibit significant metabolic
insulin resistance. (Am
J Cardiol [2002] 89:696-703) Chronic
heart failure (HF) is associated with insulin resistance.
Putative mechanisms of insulin resistance are abnormal
skeletal muscle blood flow and antagonism of insulin
action due to sympathetic nervous system activation. We
measured insulin sensitivity, the vasoactive properties
of insulin, and the association between insulin
resistance and markers of neurohormonal activation in 10
patients with chronic HF and in 9 healthy controls.
Noninvasive hemodynamic measurements and an
hyperinsulinemic, euglycemic clamp were used. Patients
were insulin resistant compared with the controls (p
<0.05 for area under insulin dose-response curve).
Insulin infusion led to a selective increase in forearm
blood flow accompanied by a decrease in mean arterial
pressure and superior mesenteric blood flow. Heart rate
decreased in patients but not in controls; however, when
baseline measurements were controlled for, there was no
difference in the overall hemodynamic response to insulin
infusion between the study groups. In univariate
analysis, age, serum creatinine, fasting insulin, and
triglyceride levels correlated inversely with insulin
sensitivity (p <0.05 for all). Cardiac output had a
significant correlation with insulin sensitivity (p
<0.05). On stepwise multiple linear regression
analysis, only age and fasting plasma insulin emerged as
significant predictors of insulin sensitivity (R2
0.613, P = 0.001). In particular, we found no evidence of
a relation between insulin sensitivity and plasma
noradrenaline. Patients with chronic HF exhibit
significant metabolic insulin resistance. Insulin
resistance is not secondary to failure of
insulin-mediated vasodilatation or sympathetic nervous
system activation and is likely due to abnormalities at
the level of the skeletal myocyte
- A
significant relationship exists between insulin
resistance and plasma concentrations of
asymmetric dimethylarginine (ADMA) (JAMA [2002] 287:
1420-1426) Context Increased
levels of asymmetric dimethylarginine (ADMA) are
associated with endothelial dysfunction and
increased risk of cardiovascular disease. Several
cardiovascular risk factors are associated with
reduced sensitivity to insulin, but elevated ADMA
concentrations have not been fully linked to the
metabolic syndrome.Objective To
evaluate the relationship between insulin
sensitivity and plasma ADMA concentrations, and
to determine whether a pharmacological treatment
that increases insulin sensitivity would also
modulate ADMA concentrations.Design, Setting,
and Subjects Cross-sectional
study, containing a nonrandomized controlled
trial component, of 64 healthy volunteers without
diabetes (42 women, 22 men; 48 with normal blood
pressure and 16 with hypertension), which was
conducted at a university medical center between
October 2000 and July 2001.Intervention Rosiglitazone
(4 mg/d for 4 weeks and then 4 mg twice daily for
8 weeks), an insulin-sensitizing agent, was given
to 7 insulin-resistant subjects with
hypertension. These subjects were studied before
and after 12-week treatment.Main Outcome
Measures Insulin sensitivity
measured by the insulin suppression test, and
fasting plasma levels of low-density lipoprotein
cholesterol, triglycerides, high-density
lipoprotein cholesterol, glucose, insulin, and
ADMA concentrations.Results Plasma
ADMA concentrations were positively correlated
with impairment of insulin-mediated glucose
disposal in nondiabetic, normotensive subjects (r
= 0.73; P<.001). Consistent with the
metabolic syndrome, ADMA levels were also
positively correlated with fasting triglyceride
levels (r = 0.52; P<.001) but
not with low-density lipoprotein cholesterol
levels (r = 0.19; P = .20). Plasma
ADMA concentrations increased in
insulin-resistant subjects independent of
hypertension. Pharmacological treatment improved
insulin sensitivity and reduced mean (SD) plasma
ADMA concentrations from 1.50 (0.30) to 1.05
(0.33) µmol/L (P = .001).Conclusion A
significant relationship exists between insulin
resistance and plasma concentrations of ADMA.
Pharmacological intervention with rosiglitazone
enhanced insulin sensitivity and reduced ADMA
levels. Increases in plasma ADMA concentrations
may contribute to the endothelial dysfunction
observed in insulin-resistant patients.
The
concentrations of proinsulin-like molecules provide a
better way to predict the incidence of CHD than those of
insulin (Diabetologia [2002] 45:327-336
Aims/hypothesis:
Higher concentrations of insulin correlate with several
coronary heart disease (CHD) risk factors and have been
shown to predict incident CHD in several studies, leading
to hypotheses concerning the proatherogenic properties of
insulin. However, in cross-sectional studies,
relationships of concentrations of the insulin precursor
molecules, proinsulin and des 31, 32 proinsulin, relate
as strongly, or more strongly, to levels of risk factors
and to (prevalent) CHD. Methods: We investigated the
relationship between concentrations of insulin, measured
with a specific assay, and of proinsulin-like molecules,
and risk factors in 1181 non-diabetic men 50-64 years old
during Phase II of the Caerphilly Study. We also related
concentrations of these molecules to incident CHD during
the 10-14 years follow-up. Results: The relationship
between concentrations of insulin, of proinsulin and of
des 31, 32 proinsulin and BMI (r = 0.36-0.45),
triglyceride (r = 0.25-0.31), high density
lipoprotein- (HDL-) cholesterol (r = -0.17 to
-0.21), systolic (r = 0.05-0.11) and diastolic
blood pressure (r = 0.11-0.15) were similarly
close, those with risk factors being somewhat and
similarly reduced after adjustment for BMI. The
correlation between insulin and of proinsulin-like
molecules and those plasminogen activator inhibitor-1
(PAI-1) antigen was also similar (r = 0.28-0.29).
There was a negative correlation between concentrations
of proinsulin-like molecules - but not insulin - and
birth weight. Insulin concentrations correlated
positively with height (r = 0.12). In logistic
regression models, concentrations of proinsulin-like
molecules, but not insulin, predicted incident of CHD
over a follow-up of 10-14 years (insulin - standardised
odds ratio (SOR) 1.30 (95 %-CI) 0.91, 1.85), p =
0.15; des 31, 32 proinsulin - SOR 1.38 (95 %-CI 1.02,
1.85), p = 0.034; sum of proinsulin-like molecules
- SOR 1.54 (95 %-CI 1.07, 2.20), p = 0.019 after
adjusting for age and BMI. The predictive ability of
these molecules was reduced by around one third after
adjustment for standard risk factors and concentrations
of tryglyceride and HDL-cholesterol, and by about half
after further adjustment for PAI-1 concentrations.
Conclusion/ interpretation: We conclude that
concentrations of proinsulin-like molecules provide a
better way to predict the incidence of CHD than those of
insulin. However, the lack of biological evidence for a
causative relationship suggests an association through a
common antecedent, and this antecedent is not likely to
be intrauterine growth retardation. [Diabetologia (2002)
45: 327-336]
- Proinsulin
is more strongly and consistently
associated with CHD than is intact insulin in
older nondiabetic men and women (Circulation.
[2002]105:1311.) Background
Insulin or insulin resistance is considered a
coronary heart disease (CHD) risk factor, but
proinsulin may have a stronger
association with CHD than insulin. The role of
sex differences in this association is unclear.
We examined the cross-sectional
association of proinsulin and insulin with CHD
in older men and women without diabetes. Methods
and Results A cross-sectional study
of community-dwelling men (n=554) and
women (n=902), 50 to 97 years of age, without
diabetes by history or oral glucose
tolerance test, was done between 1992
and 1996; plasma levels of intact insulin,
proinsulin, and C-peptide were
measured by radioimmunoassay. Based on
questionnaire, medical history, or ECG
abnormalities, 25% of men (n=136) and 24%
of women (n=214) had prevalent CHD. All insulin
variables were positively correlated
with CHD risk factors. Compared with those
without CHD, men and women with CHD had
significantly higher levels of
proinsulin. Women but not men with CHD also had
higher levels of C-peptide and fasting and
postchallenge insulin. Only proinsulin
was significantly and independently associated
with prevalent CHD in both men (OR=2.41, 1.42 to
4.11) and women (OR=1.80, 1.22 to 2.64)
(adjusted for age, body mass index,
systolic blood pressure, and HDL cholesterol).
Similar analyses for fasting and
postchallenge intact insulin and for C-peptide
showed that among these three variables, only
postchallenge insulin was
significantly associated with CHD, and only in
women. Conclusions
In older nondiabetic men and women, proinsulin
was more strongly and consistently
associated with CHD than was intact
insulin.
Chronic
vitamin C deficiency does not influence the
initiation or progression of atherosclerotic plaques but
severely compromises collagen deposition and
induces a type of plaque morphology that is
potentially vulnerable to rupture (Circulation. [2002];105:1485.) Background
Oxidative stress is thought to play an important role
in atherogenesis, suggesting that antioxidants could
prevent coronary artery disease. However, the
efficacy of vitamin C in reducing
atherosclerosis is debatable in humans and has not been
tested rigorously in animals. Methods
and Results Gulo-/-Apoe-/-
mice were used to test a hypothesis that
chronic vitamin C deficiency enhances the
initiation and development of atherosclerosis. These mice
are dependent on dietary vitamin C because of the
lack of L-gulonolactone-gamma-oxidase and are
prone to develop atherosclerosis because of lacking apolipoprotein
E. Beginning at 6 weeks of age, the Gulo-/-Apoe-/-
mice were fed regular chow or Western-type diets
containing high fat and supplemented with
either 0.033 g or 3.3 g/L of vitamin C in
their drinking water. This regimen produced mice with
chronically low vitamin C (average 1.5 µg/mL in plasma)
or high vitamin C (average 10 to 30 µg/mL in
plasma). Morphometric analysis showed that
within each sex, age, and diet group, the
sizes of the atherosclerotic plaques were not different
between low vitamin C mice and high vitamin C mice. However,
advanced plaques in the low vitamin C mice had
significantly reduced amounts of Sirius
redstaining collagen (36.4±2.2% versus
54.8±2.3%, P<0.0001), larger necrotic cores
within the plaques, and reduced fibroproliferation
and neovascularization in the aortic
adventitia. Conclusions
Chronic vitamin C deficiency does not influence the
initiation or progression of atherosclerotic plaques but
severely compromises collagen deposition and
induces a type of plaque morphology that is
potentially vulnerable to rupture.
- TNF-[alpha]
concentration is associated with degrees of early
atherosclerosis (European Heart Journal [2002]
23(5):376-383) Aims Tumour necrosis
factor-[alpha] (TNF-[alpha]) is a proinflammatory
cytokine, which is implicated in some metabolic
disorders and may play a role in the development
of cardiovascular disease. We examined whether
plasma TNF-[alpha] is related to established
cardiovascular risk indicators, plasma levels of
soluble cellular adhesion molecules and carotid
artery intima-media thickness determined by
ultrasound examination in a population-based
cohort of 96 healthy 50-year-old men. Methods
and Results TNF-[alpha] and cellular adhesion
molecules were measured with enzyme-linked
immunosorbent assays. Plasma TNF-[alpha]
concentration was associated with systolic and
diastolic blood pressure, degrees of alimentary
lipaemia, plasma very low density lipoprotein
triglyceride, low density lipoprotein (LDL)
cholesterol concentrations and peak LDL particle
size. Two indices of insulin resistance as well
as all soluble cellular adhesion molecules
correlated positively with TNF-[alpha]. The
plasma TNF-[alpha] concentration was associated
with common carotid intima-media thickness in
univariate analysis. In contrast, soluble
E-selectin and postprandial triglycerides, but
not TNF-[alpha], were independent determinants of
common carotid intima-media thickness. Conclusion
The plasma TNF-[alpha] concentration is
associated with degrees of early atherosclerosis
and correlates with metabolic and cellular
perturbations that are considered important for
the vascular process.
In CHD, vWF and
tPAag -but not thrombomodulin - are
independent markers of atherosclerosis. (Thrombosis
Research [2002] 105(1):25-31) von
Willebrand factor (vWF), thrombomodulin and tissue
plasminogen activator antigen (tPAag) are regarded as
markers of endothelial activation and/or damage. Elevated
levels have been associated with atherosclerotic disease
states. The aim of the present study was to compare the
levels of vWF, thrombomodulin and tPAag in patients with
coronary heart disease (CHD) and matched healthy
individuals to see if they discriminated significantly
between the study groups also after adjustment for
established CHD risk factors. Patients (n=193) in various
stages of CHD and matched controls (n=193) were included.
To evaluate possible influence of acute phase reaction,
reinvestigation was performed after 6 months. We observed
elevated levels of vWF (P<.001) and tPAag (P<.001)
but not thrombomodulin (P=.082) in CHD patients when
compared to controls, still statistically significant
after 6 months and also after adjustment for established
risk factors. Our results indicate that vWF and tPAag but
not thrombomodulin in the present population are
independent markers of atherosclerosis.
- Perilipin
Gene is Potentially Involved in the Rupture of
Human Atherosclerotic Plaques (Circulation
Research. [2001] 89:547.) Although
rupture of an atherosclerotic plaque is
the major cause of acute vascular occlusion, the
exact molecular mechanisms underlying
this process are still poorly understood. In
this study, we used suppression subtractive
hybridization to make an inventory of
genes that are differentially expressed in
whole-mount human stable and ruptured plaques.
Two libraries were generated, one
containing 3000 clones upregulated and one containing
2000 clones downregulated in ruptured plaques.
Macroarray analysis of 500 randomly
chosen clones showed differential expression
of 45 clones. Among the 25 clones that
showed at least a 2-fold difference in
expression was the gene of perilipin, upregulated
in ruptured plaques, and the genes coding
for fibronectin and immunoglobulin
lambda-chain, which were downregulated in
ruptured plaques. Reverse
transcriptasepolymerase chain reaction
analysis on 10 individual ruptured and 10
individual stable plaques showed a
striking consistency of expression for the clones
SSH6, present in 8 ruptured and 2 stable plaques,
and perilipin, expressed in 8 ruptured
plaques and completely absent in
stable plaques. Localization studies of both
perilipin mRNA and protein revealed
expression in cells surrounding the cholesterol
clefts and in foam cells of ruptured
atherosclerotic plaques. No expression
was observed in nondiseased artery, and only a
few cells in the shoulder region of stable
plaques tested positive for perilipin.
In conclusion, this study shows that it is
possible to identify genes that are
differentially expressed in whole-mount stable
or ruptured atherosclerotic plaques. This
approach may yield several potential
regulators of plaque destabilization.
Perilipin
ablation results in a lean mouse with aberrant adipocyte
lipolysis, enhanced leptin production [per adipocyte
mass], a resistance to diet-induced obesity, as well as a
tendency toward insulin resistance (Proc. Natl. Acad. Sci. USA [2001] 98:
6494-6499) Perilipin coats the lipid droplets
of adipocytes and is thought to have a role in regulating
triacylglycerol hydrolysis. To study the role of
perilipin in vivo, we have created a perilipin knockout
mouse. Perilipin null (peri(-/-)) and wild-type
(peri(+/+)) mice consume equal amounts of food, but the
adipose tissue mass in the null animals is reduced to
approximately 30% of that in wild-type animals. Isolated
adipocytes of perilipin null mice exhibit elevated basal
lipolysis because of the loss of the protective function
of perilipin. They also exhibit dramatically attenuated
stimulated lipolytic activity, indicating that perilipin
is required for maximal lipolytic activity. Plasma leptin
concentrations in null animals were greater than expected
for the reduced adipose mass. The peri(-/-) animals have
a greater lean body mass and increased metabolic rate but
they also show an increased tendency to develop glucose
intolerance and peripheral insulin resistance. When fed a
high-fat diet, the perilipin null animals are resistant
to diet-induced obesity but not to glucose intolerance.
The data reveal a major role for perilipin in adipose
lipid metabolism and suggest perilipin as a potential
target for attacking problems associated with obesity.
- Absence
of perilipin results in leanness and reverses
obesity in Lepr(db/db) mice (Nat Genet [2000] 26::474-9)
Obesity is a disorder
of energy balance. Hormone-sensitive lipase (HSL)
mediates the hydrolysis of triacylglycerol, the
major form of stored energy in the body.
Perilipin (encoded by the gene Plin), an
adipocyte protein, has been postulated to
modulate HSL activity. We show here that targeted
disruption of Plin results in healthy mice that
have constitutively activated fat-cell HSL. Plin
-/- mice consume more food than control mice, but
have normal body weight. They are much leaner and
more muscular than controls, have 62% smaller
white adipocytes, show elevated basal lipolysis
that is resistant to beta-adrenergic agonist
stimulation, and are cold-sensitive except when
fed. They are also resistant to diet-induced
obesity. Breeding the Plin -/- alleles into
Leprdb/db mice reverses the obesity by ncreasing
the metabolic rate of the mice. Our results
demonstrate a role for perilipin in reining in
basal HSL activity and regulating lipolysis and
energy balance; thus, agents that inactivate
perilipin may prove useful as anti-obesity
medications.
Triglycerides
>200 mg/dl (But Not
Triglyceride Reduction)
Strongly Associate with Stroke Risk in BIP (Circulation [2001] 104:2892)Background
Despite unclear associations between blood lipids,
including fractionated cholesterol and triglycerides,
and stroke, recent evidence demonstrates that
lipid-modifying agents decrease the risk of
stroke in patients with coronary heart disease
(CHD). Methods and Results
Patients with documented CHD who were screened
for but not included in the Bezafibrate Infarction Prevention
study and had no history of stroke or transient ischemic
attack (TIA) (n=11 177) were followed up. At
baseline, medical histories were obtained and
blood lipids assessed at a central study
laboratory. During a 6- to 8-year follow-up period, 941
patients were identified as having nonhemorrhagic
cerebrovascular disease, of whom 487 had
verified ischemic stroke (per clinical findings
and brain CT) or TIA. Patients experiencing an ischemic
stroke/TIA had higher mean levels of triglycerides,
lower levels of HDL cholesterol, and lower
percentages of cholesterol contained in the
HDL cholesterol moiety (%HDL; P<0.01 for all).
In a logistic regression model, the adjusted
ORs for developing an ischemic stroke/TIA were
1.27 (95% CI 1.01 to 1.60) associated with
triglycerides >200 mg/dL and 0.87 (95% CI 0.78 to
0.97) associated with a 5% decrease in %HDL.
The increased risk associated with high
triglycerides was found across subgroups of age, sex,
patient characteristics, and cholesterol fractions.
Conclusions High triglycerides
constitute an independent risk factor for
ischemic stroke/TIA across subgroups of age, sex,
patient characteristics, and cholesterol fractions,
whereas high %HDL was an independent
protective factor among patients with CHD.
These findings support the role of blood lipids,
including triglycerides, as important
modifiable stroke risk factors.
- A
major Israeli study of 3090 patients - the
Bezafibrate Infarction Prevention trial - showed
no significant reduction in fatal or non-fatal MI
or sudden death from triglyceride lowering or HDL
raising (Circulation
[2000] 102:21)BackgroundCoronary
heart disease patients with low high-density
lipoprotein cholesterol (HDL-C) levels,
high triglyceride levels, or both are
at an increased risk of cardiovascular events,
but the clinical impact of raising
HDL-C or decreasing triglycerides remains
to be confirmed. Methods and
ResultsIn a double-blind trial, 3090
patients with a previous myocardial
infarction or stable angina, total cholesterol
of 180 to 250 mg/dL, HDL-C 45 mg/dL,
triglycerides <300 mg/dL, and
low-density lipoprotein cholesterol <180 mg/dL
were randomized to receive either 400
mg of bezafibrate per day or a placebo; they
were followed for a mean of 6.2 years. The
primary end point was fatal or
nonfatal myocardial infarction or sudden death.
Bezafibrate increased HDL-C by 18% and reduced
triglycerides by 21%. The frequency of
the primary end point was 13.6% on bezafibrate
versus 15.0% on placebo (P=0.26). After
6.2 years, the reduction in the
cumulative probability of the primary end point
was 7.3%, (P=0.24). In a post hoc analysis
in the subgroup with high baseline
triglycerides (>200 mg/dL), the reduction in
the cumulative probability of the
primary end point by bezafibrate was
39.5% (P=0.02). Total and noncardiac
mortality rates were similar, and
adverse events and cancer were equally
distributed. ConclusionsBezafibrate
was safe and effective in elevating HDL-C
levels and lowering triglycerides. An overall
trend in a reduction of the incidence
of primary end points was observed. The
reduction in the primary end point in patients
with high baseline triglycerides
(>200 mg/dL) requires further confirmation.
Elevated plasma
CRP levels significantly predict the risk of future
ischemic stroke and TIA in the elderly and independently
of other cardiovascular risk factors. (Stroke. [2001] 32:2575) Background
The role of C-reactive protein (CRP) as a
novel plasma marker of atherothrombotic disease is
currently under investigation. Previous
studies have mostly related CRP to coronary
heart disease, were often restricted to a case-control
design, and failed to include pertinent risk
factors to evaluate the joint and net effect
of CRP on the outcome. We related plasma CRP
levels to incidence of first ischemic stroke or transient
ischemic attack (TIA) in the Framingham Study
original cohort. Methods
There were 591 men and 871 women free of
stroke/TIA during their 1980 to 1982 clinic examinations,
when their mean age was 69.7 years. CRP levels were
measured by using an enzyme immunoassay on
previously frozen serum samples. Analyses were
based on sex-specific CRP quartiles. Risk ratios (RRs)
were derived, and series of trend analyses were
performed. Results
During 12 to 14 years of follow-up, 196 ischemic
strokes and TIAs occurred. Independent of age, men in
the highest CRP quartile had 2 times the risk of ischemic
stroke/TIA (RR=2.0, P=0.027), and women had
almost 3 times the risk (RR=2.7, P=0.0003)
compared with those in the lowest quartile. Assessment
of the trend in risk across quartiles showed unadjusted
risk increase for men (RR=1.347, P=0.0025)
and women (RR=1.441, P=0.0001). After
adjustment for smoking, total/HDL cholesterol, systolic
blood pressure, and diabetes, the increase in risk across
CRP quartiles remained statistically significant for
both men (P=0.0365) and women (P=0.0084).
Conclusions Independent
of other cardiovascular risk factors, elevated
plasma CRP levels significantly predict the
risk of future ischemic stroke and TIA in the elderly.
- Pravastatin
Treatment Removes the Increased Effect of LARGE
Low-Density Lipoprotein Size upon Coronary Events
(JAMA.
[2001] 286:1468-1474) Context Small
low-density lipoprotein (LDL) particle size has
been hypothesized to be a risk factor for
coronary heart disease (CHD). Animal models link
large LDL to atherosclerosis. However, the strong
association between small LDL and other risk
factors, particularly triglyceride levels,
impedes determining whether LDL size
independently predicts CHD in humans.Objective To
examine whether LDL size is an independent
predictor of recurrent coronary events in
patients with known CHD, as opposed to a marker
for other lipid abnormalities.Design and
Setting Prospective, nested
case-control study in the Cholesterol and
Recurrent Events (CARE) trial, a randomized
placebo-controlled trial of pravastatin conducted
in 1989-1996.Participants Survivors
of myocardial infarction with typical LDL
concentrations (416 cases and 421 controls).Main
Outcome Measure Subsequent
myocardial infarction or coronary death during
the 5-year follow-up, analyzed by quintile of LDL
particle size and by treatment group.
Results Overall, the mean LDL size
was identical in cases and controls (25.6 nm). In
patients in the placebo group, large LDL
predicted coronary events in models adjusted only
for age (relative risk [RR], 1.79; 95% confidence
interval [CI], 1.01-3.17) and for age and lipid
and nonlipid risk factors (RR, 4.00; 95% CI,
1.81-8.82), comparing those in the highest (mean,
26.6 nm) and lowest (mean, 24.5 nm) quintiles of
LDL size. This increased risk was not present in
those taking pravastatin (age-adjusted analysis:
RR, 0.98; 95% CI, 0.47-2.04; P = .046 for
interaction for a difference in the effect of LDL
size on coronary events between the placebo and
treatment groups; multivariable analysis: RR,
1.33; 95% CI, 0.52-3.38; P = .11 for
interaction).Conclusions Large
LDL size was an independent predictor of coronary
events in a typical population with myocardial
infarction, but the adverse effect was not
present among patients who were treated with
pravastatin. Identifying patients on the basis of
LDL size may not be useful clinically, since
effective treatment for elevated LDL cholesterol
concentrations also effectively treats risk
associated with large LDL.
Plasma leptin concentration is a
novel and independent risk factor for CHD in WOSCOPS (Diabetologia [2001] 44
(Suppl 1): A315. EASD 37th Annual Meeting,
#1209)
IKK-ß May
Underly the Inflammatory Etiology of the Dysmetabolic
Syndrome (Science
[2001] 293:1673-1677)
Augmentation
of the synthesis of plasminogen activator inhibitor
type-1 by precursors of insulin. A potential risk factor
for vascular disease. (Circulation [1994] 89:321-330) BACKGROUND:
Both vascular disease and elevated concentrations in
plasma of plasminogen activator inhibitor type-1 (PAI-1)
are prominent in patients with non-insulin-dependent
diabetes mellitus (NIDDM). We and others have
hypothesized that the increased PAI-1 may contribute to
acceleration of atherosclerosis in this condition and in
other states characterized by insulin resistance as well.
Surprisingly, however, elevations of PAI-1 decrease when
type II diabetic patients are treated with exogenous
insulin, as do circulating concentrations of the
precursor of insulin, proinsulin, in plasma. Accordingly,
the increased PAI-1 in patients with NIDDM may reflect
effects of precursors of insulin rather than or in
addition to those of insulin itself. To assess this
possibility directly, this study was performed to
identify potential direct effects of proinsulin and
proinsulin split products on synthesis of PAI-1 in liver
cells, thought to be the major source of circulating
PAI-1 in vivo. METHODS AND RESULTS: Hep G2 cells (highly
differentiated human hepatoma cells) were exposed to
human proinsulin, des(31,32)proinsulin and
des(64,65)proinsulin (split products of proinsulin), or
C-peptide. Accumulation of PAI-1 in conditioned media
increased in a time- and concentration-dependent fashion
in response to the two des-intermediates [3.3-fold with
des(31,32)proinsulin and 4.5-fold with
des(64,65)proinsulin]. C-peptide elicited no increase.
Stimulation was transduced at least in part by the
insulin receptor as shown by inhibition of stimulation by
insulin receptor antibodies, mediated at the level of
PAI-1 gene expression as shown by the 2.2- to 2.9-fold
increases in steady-state concentrations of PAI-1 mRNA,
and indicative of newly synthesized protein as shown by
results in metabolic labeling experiments. CONCLUSIONS:
Our results are consistent with the hypothesis that
precursors of insulin (proinsulin and proinsulin split
products), known to be present in relatively high
concentrations in plasma in patients with NIDDM and
conditions characterized by insulin resistance, may
directly stimulate PAI-1 synthesis, thereby attenuating
fibrinolysis and accelerating atherogenesis.
Diabetes and ischemic heart disease interact
to accelerate the progression of myocardial dysfunction (JACC [2000] 38:421-428)
Dyslipidemia
Is Predictive of Macrovascular Events in Type 2 Diabetes
While Glycemia Is Not (ADA
61st SS, Abstract #1910-PO, June 2001)
Losing Weight
Returns Compromised T-Cell Function To Normal Via Reduced
a-TNF (Clin
Endocrinol [2001] 54(3):347-354 )
Opening of
sarcolemmal KATPchannels underlies ST
elevation during ischemia" (Circulation
Res. [2000] 87:837)
High dietary
glycemic index and high glycemic load are associated with
a lower concentration of plasma HDL-C.(Arch Intern Med. [2001]161:572-576
Protein Kinase
C action decreases the Hill coefficient of ATP binding to
cardiac KATP channels, thereby increasing their open
probability at physiological ATP concentrations (PNAS [2000] 10:1073)
CLA-1/SR-BI Is
Expressed in Atherosclerotic Lesion Macrophages and
Regulated by Activators of Peroxisome
Proliferator-Activated Receptors (Circulation[2000]101:2411)
Glycation
of CD59 may form the molecular basis for a link between
complement and the vascular complications of diabetes (PNAS [2000] 97:5450-5455)
Hyperinsulinemia
modest association with CV mortality is largely explained
by obesity, hypertension, and dyslipidemia" (Arch Intern Med.
[2000]160:1160-1168)
Prolonged
hyperlipidemia - independent of insulin - may contribute
to increased fat metabolism and storage as a result of
FAT/CD36, PPAR-2, leptin, UCP-2, UCP-3, and TNF-alpha induction.
Diabetes
[2000] 49:319324
JAMA
publishes *VA VOODOO* study - utilizing such inane
concepts as *utility index* of blindness and *quality
adjusted life years* as well as innumerable assumptions
predicting *days of blindness* - to suggest that yearly
visual screens in type 2 patients are not
cost-effective....(JAMA
[2000]283:889-896)
In multivariate Cox models, the
age-adjusted hazard ratio for insulin resistance factor
during the 22-year Helsinki Policemen Study
follow-up was 1.28 (95% CI 1.10 to 1.50) with regard
to CHD risk and 1.64 (95% CI 1.29 to 2.08) with
regard to stroke risk. Lipid factor predicted
the risk of CHD but not that of stroke, and
lifestyle factor predicted a reduced CHD risk. Factor
analysis including only 6 risk factor
variables proposed to be central components of
insulin resistance syndrome (body mass index, subscapular
skinfold, AUC insulin, AUC glucose, mean blood
pressure, and triglycerides) produced only a
single insulin resistance factor that
predicted the risk of CHD and stroke independently of
other risk factors....(Arteriosclerosis,Thrombosis and
Vascular Biology[2000]20:538)
Platelet-derived
thrombogenesis in stable coronary patients associates
weakly with blood glucose (R2 = 0.19, p < 0.008), and apo-B (R2 = 0.18, p = 0.002) at a threshold glucose value of
88.2 mg/dl (JACC[2000]35:300-307)
In normal
glucose tolerant offspring of type 2 diabetics, PAI-1
activity was correlated with
plasma PAI-1 antigen
level (r = 0.40, P = 0.02), fibrinogen (r
= 0.45, P = 0.01), and HDL cholesterol (r =
0.36, P = 0.04). However, tPA
antigen level, fasting and postload plasma
glucose and insulin, total
cholesterol, triglycerides, WHR, and BMI did NOT
correlate with PAI-1 activity
Physiologic
elevation in the local plasma insulin concentration
increases coronary blood flow in the absence of any
increase in myocardial oxygen demand or consumption.
These observations are consistent with insulin-mediated
elaboration of vasoactive and/or paracrine factors within
the coronary circulation.
Fasting
Insulinemia Appears to Associate with Measures of BOTH
Increased (t-PA antigen) AND Decreased (PAI-1 antigen)
Fibrinolytic Potential
Diabetic
subjects have significantly (P<0.001)
more increased Dicarboxylic Acid (DA) excretion in urine
than corresponding healthy subjects. The yields of DA's
in each group decreased in the order
adipic>suberic>sebacic acid. Being stable and
easily detectable compounds, DA's may be considered
potential markers of oxidative attack on PUFA in diabetes
Coronary
Disease in Type 1's Correlates with Depression, NOT
Glucose. Lower Extremity Arterial Disease, however, Does
Correlate with Blood Glucose in Type 1's
LDL
size is not a predictor of CHD events in elderly white
subjects after controlling for diabetes status
Nonfasting Serum Glucose and Insulin Concentrations
Associate Significantly with the Risk
of Stroke
HDL (HDL2) from poorly-controlled diabetics is abnormal and does not inhibit LDL-oxidation or Apo-A1
fragmentation or HDL2-associated
platelet-activating factor
acetylhydrolase activity as well as non-diabetic HDL(HDL2) in vitro
Should
we recognize another class of diabetes called "Prandial
Diabetes" with different risk factors? (The new
fasting ADA criteria seem to be less predictive than the
WHO criteria for the burden of cardiovascular disease
associated with abnormal glucose in the elderly.)
Protein-Rich
Diets May Reduce Heart Disease Risk
Western-Diet (high in
meats and fats) protective against
stroke dementia: Honolulu-Asia Aging Study
Hypertension correlates with Renal Disease and NOT Cardiovascular Disease in the Pima Diabetic
Homocysteine significantly predicts
atherosclerotic events in the
post-menopausal period independent of diabetes
Adipose-Cells secrete IL-6 which correlates with BMI, TNF-alfa, insulin
resistance, markers of endothelial
dysfunction, and the inflammatory marker
C-Reactive Protein (CRP)
top of the
news
Reload The
National Diabetes Center Frames
Home Page
|
|